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“To kill an error is as good a service as, and sometimes even better than, 
the establishing of a new truth or fact.” 
    
Charles Darwin 
 
 
 
 
“A day without laughter is a day wasted.” 
    
Charlie Chaplin 
  
 
  
 
ABSTRACT 
Drug usage has increased steadily, and the more drugs used, the higher the risk for 
adverse effects or loss of effect due to drug-drug interactions. For drug prescribers it is 
difficult to know what drugs a patient is taking and whether they interact. 
Computerizing of health care records has made it possible to connect patients’ drug 
lists to clinical decision support systems giving the prescriber information about e.g. 
drug-drug interactions, duplicated prescriptions and drugs in pregnancy. The aim of this 
thesis is to create a knowledge base suitable for usage in decision support systems, to 
evaluate the database in clinical practice, and to use existing clinical databases to create 
new knowledge about possible drug-drug interactions and their mechanisms.  
 
Paper I is a description of how the knowledge base SFINX was created. The 
publication describes handling of substances and drug formulations. Standardization of 
literature searches and text formulations, classification of interactions, structuring of 
interaction texts, basis for recommendations and the process of approval is also 
discussed.  
 
In paper II, the interaction between lamotrigine and quetiapine was studied using 
therapeutic drug monitoring data. Patients exposed to both quetiapine and lamotrigine 
were matched with controls exposed to quetiapine alone. The dose-corrected quetiapine 
concentration was 58% lower in patients co-treated with lamotrigine than in patients 
treated with quetiapine alone, possibly due to induction of quetiapine metabolism by 
lamotrigine. 
 
In paper III, the influence of mutations in the CYP2C9 gene on the interaction between 
simvastatin and warfarin was studied. In patients with a CYP2C9*3 allele, the warfarin 
maintenance dose was 25% lower if treated with simvastatin, according to the results 
from multiple regression. No significant interaction could be observed in patients 
lacking the *3 allele.  
 
Paper IV was a questionnaire study where we collected information about how SFINX 
is used and how the database is perceived by the users of the web version. We found 
that the database is often used when the prescriber/pharmacist sees the patient, that the 
information influences the treatment of the patient, and that the database is used to learn 
more about interactions.  
 
In paper V, we investigated if integration of SFINX into electronic health care records 
prevented the prescribing of drug combinations leading to potentially serious drug-drug 
interactions in primary health care. When comparing prescriptions between a period 
before integration of SFINX and a period after integration, we found that the 
prevalence of potentially serious drug-drug interactions decreased significantly by 17%.  
  
 
 
 
  
 
SAMMANFATTNING 
Läkemedelsanvändningen har ökat stadigt och ju fler läkemedel som används desto 
större är risken för läkemedelsinteraktioner som kan leda till biverkningar eller 
utebliven effekt. För den som skriver ut läkemedel är det väldigt svårt att veta dels vilka 
läkemedel patienten tar, dels om dessa interagerar med varandra. Datorisering av 
patientjournaler gör det möjligt att koppla patientens läkemedelslista mot så kallade 
förskrivarstöd som ger förskrivaren information om t.ex. läkemedelsinteraktioner, 
dubbelförskrivningar och läkemedel under graviditet.  Syftet med denna avhandling är 
att utveckla en kunskapsdatabas om läkemedelsinteraktioner, lämplig att använda i 
förskrivarstöd, att utvärdera databasen i klinisk praktik, samt att använda befintliga 
kliniska databaser som grund för att skapa ny kunskap om möjliga 
läkemedelsinteraktioner och mekanismer för dessa. 
 
Det första delarbetet beskriver hur kunskapsdatabasen SFINX skapades. Artikeln  
beskriver hur substanser och beredningsformer hanteras. Vidare beskrivs 
standardisering av texter, hur interaktionerna klassificeras samt arbetet med att skapa 
dokumentation för sökningar av litteratur och godkännande av interaktionstexterna. 
 
I delarbete II studerades interaktionen mellan lamotrigin, ett antiepileptikum, och 
quetiapin, ett antipsykotikum, med hjälp av data från rutinmässigt utförda mätningar av 
läkemedelskoncentrationer. Patienter exponerade för quetiapin och lamotrigin 
matchades med kontroller enbart exponerade för quetiapin. Koncentration-doskvoten 
för quetiapin var signifikant lägre hos de patienter som även behandlats med 
lamotrigin. Den doskorrigerade quetiapinkoncentrationen befanns vara 58% lägre än 
hos patienter som ej behandlats med lamotrigin, vilket kan tolkas som att lamotrigin 
inducerat nedbrytningen av quetiapin.  
 
I delarbete III studerades om mutationer i genen för CYP2C9, det viktigaste enzymet 
för nedbrytning av warfarin, påverkar interaktionen mellan simvastatin och warfarin. 
Hos patienter med en *3 allel var dosbehovet av warfarin 25% lägre om de behandlades 
med simvastatin enligt den multipla regressionen. Ingen signifikant interaktion kunde 
ses hos patienter som saknade *3 allelen. 
 
Delarbete IV var en enkätstudie där vi samlade information om hur SFINX används 
och hur databasen uppfattas av användarna av webbversionen. Vi fann att databasen 
ofta används när förskrivaren/farmaceuten möter patienten, att informationen påverkar 
handläggning av patienten och att användarna använder databasen för att lära sig mer 
om interaktioner. 
 
I delarbete V undersöktes om införandet av SFINX i journalsystemet minskar 
primärvårdens förskrivning av läkemedelskombinationer som leder till potentiellt 
allvarliga interaktioner. Baserat på förskrivningar under en period innan införandet och 
en efter fann vi att förekomsten av potentiellt allvarliga interaktioner minskade med 
17% i den grupp som fått tillgång till SFINX. 
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1 INTRODUCTION 
1.1 HISTORY 
People have tried to cure diseases with remedies since prehistoric time. In the early 
days, remedies were usually from herbs or animals. Chemically pure drugs were 
introduced in the 1920s [1], and since then usage and knowledge about drugs have 
increased rapidly. It would take 25-30 years after purified drugs were introduced until it 
became known that drugs can influence the effect of each other. 
 
Cases of a remarkable interaction between monoamino oxidase (MAO) inhibitors, used 
for depression, and tyramine rich food were published in 1963 [2;3]. Hypertensive 
crisis starting half an hour up to two hours after ingestion of mature cheeses, such as 
cheddar, was reported in nine patients. At the time of these reports, the mechanism for 
this interaction was unknown, but soon it was discovered that the metabolism of 
tyramine, in the cheese, was inhibited by the antidepressants, causing the observed 
symptoms [4].  
 
Some years before the MAO-inhibitor interaction was described, unexpected drug 
interactions causing adverse effects such as hypoglycemia in phenylbutazone (also 
known as butazolidine [5] and tolbutamide treated patients [6], and increased 
anticoagulation in phenprocoumon treated patients [7] were reported. In 1956, a single 
case study was published where the exposure to ethyl biscoumacetate (tromexan, an old 
coumarin anticoagulant) was increased two-fold by concomitant therapy with 
phenylbutazone. The same authors also reported being aware of over fifty cases of 
increased anticoagulative effect of phenprocoumon in patients treated with 
phenylbutazone [7]. Later it was shown that phenylbutazone is an inhibitor of 
cytochrome P-450 2C9 (CYP2C9) [8], the enzyme responsible for metabolism of 
tolbutamide [9] and partially involved in the metabolism of phenprocoumon [10]. It is 
likely that this may have been the mechanism behind the interaction between ethyl 
biscoumacetate and phenylbutazone.  In 1963, it was demonstrated that the CYP2C9 
inhibitor [11] sulphapenazole increased the blood concentration of the oral antidiabetic 
tolbutamide in three patients [12].  
 
After these initial findings, the knowledge of drug interactions increased rapidly. It was 
found that many drugs may induce or inhibit the metabolism of other drugs [13;14]. 
Studies on monozygotic and dizygotic twins revealed that genetics influences drug 
exposure [15-17]. Knowledge of cytochrome P-450 enzymes and their importance for 
drug metabolism was discovered [18]. In vitro methodology was improved, and drug-
drug interaction studies were performed both humans and in animals. 
 
In 1970, the Swedish authorities required pharmaceutical companies to give annual 
updates regarding drug interactions in the Swedish catalogue of approved medical 
products (FASS) [19].  This made drug interaction information much easier for the 
prescribers to access, but the clinical relevance of the interactions was almost 
impossible to ascertain. In 1997, a system classifying drug interactions according to 
clinical relevance and level of documentation was introduced in FASS [20]. This 
information was later made electronically available, and was used as the base for the 
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first Swedish electronic drug interaction database published on the Internet. It also was 
made available in the decision support system Janus toolbar [21]. 
 
Today, both the American Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) have clear guidelines [22;23] on how to perform drug 
interaction studies before market approval and often require additional studies. Still 
prescribers need to evaluate the clinical relevance of interactions mentioned in the 
summary of product characteristic (SPC), since much of the information is based on in 
vitro data only.  Furthermore, SPC texts have been shown to include only 33% of the 
drug interactions described in the literature [24]. Drug interaction warning systems are 
available, but the information found in different sources varies greatly as does the 
structure of the systems. 
 
1.2 BASIC CLINICAL PHARMACOLOGY 
1.2.1 Pharmacodynamics 
A drug is not an intelligent creature, and it does not work as a target-seeking missile. 
The drug is usually distributed within the body and many drugs are either agonists, 
activating certain receptors found within the body, or antagonists blocking activation of 
the receptor. One example of an agonist is morphine, which exerts its effects on opioid 
receptors that naturally bind endogenous endorphins.  When morphine binds to the 
receptors it has effects similar to the endogenous substance and thereby inhibits pain, 
increases well-being and also causes side effects such as constipation and nausea. An 
example of an antagonist is haloperidol, which binds to dopamine D2 receptors. 
Haloperidol is used for treatment of psychotic disorders and it inhibits the stimulatory 
effect of dopamine on the D2 type of the dopamine receptors.   
 
For a drug to be effective it needs to reach the place where it exerts its effect. If the 
concentration is too high the drug will, with rather few exceptions, cause adverse 
effects either because too much of effect of the drug, or because it binds to other 
receptors. Some drugs such as tricyclic antidepressants exert, in a concentration 
dependent manner, an unwanted anticholinergic effect by binding to muscarinic 
acetylcholine receptors, inhibiting the effect of endogenous acetylcholine. Inhibition of 
muscarinic receptors causes anticholinergic side effects such as dry mouth, dry eyes, 
constipation and urinary retention. 
 
The drug concentration at the target site is usually not measurable by simple methods, 
but it is often assumed to be correlated with the blood concentration of the drug.  The 
aim of drug therapy is, usually, to treat the patient with the lowest effective dose in 
order to avoid adverse effects.  
 
The target drug concentration is the concentration needed to achieve sufficient effect 
without intolerable side effects. This is called the therapeutic interval or therapeutic 
window.  
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1.2.2 Drug distribution 
When a drug enters the body, it is distributed within the body and the pattern is 
dependent on many factors such as molecular size, lipophilicity of the drug, and ability 
to be transported by active transporters. Some drugs are found in a high concentration 
in the blood, whereas other drugs are highly bound to tissues such as body fat.  
 
If the drug is taken as a tablet, it first enters the stomach where the tablet is dissolved 
(unless it is covered with a layer that resists stomach acidity). The drug is taken up into 
the blood, usually via the intestinal mucosa either by passive diffusion or by active 
transport, and distributed into other body tissues.  
 
The body’s handling of the drug is called pharmacokinetics and includes absorption, 
distribution, transport, metabolism and excretion. 
 
1.2.3 Drug transport 
Some drugs are transported by active membrane transporters, which may influence 
their distribution. Transporters can be found at many places such as in the intestines, in 
the liver, in the kidney, and in the blood-brain barrier. The blood-brain barrier separates 
brain fluid from the blood and it protects the brain from toxic substances.  
 
One of the most important drug transporters is P-glycoprotein (P-gp). The role of P-gp 
appears to be to limit body damage due to xenobiotics.  P-gp can be found in the 
intestines where it acts as an efflux pump, carrying already absorbed drugs back into 
the intestinal lumen, thereby decreasing the net uptake of the drug. P-gp is also found in 
the blood-brain barrier, where it transports substances from the brain back to the 
circulation [25]. Examples of P-gp substrates include digoxin [26] and tacrolimus [27]. 
Some cancer cells are overexpressing P-gp , making them resistant to certain 
chemotherapeutic agents such as etoposide and vinblastine [28]. 
 
Another transporter that has been shown to alter drug pharmacokinetics is the organic 
anion transporter protein B1B (OATPB1B) which carries drugs into hepatocytes. 
OATPB1B transports many drugs, and some examples are rifampicin, simvastatin acid, 
bosentan and caspofungin [29]. Statins exert their effects by inhibiting 3-hydroxy-3-
ethylglutaryl-coenzyme A (HMG-CoA) in the liver and decreased OATPB1B transport 
may cause increased statin concentration,  adverse effects, and decreased efficacy [30].  
 
There are also many transporters found in the proximal tubule of the kidney, 
transporting molecules into or out of the urine. Many drugs are actively excreted into 
urine. For example, organic cation transporters (OCTs) transport positively charged 
drugs such as metformin [31] from the blood into the proximal tubule.  
 
1.2.4 Drug metabolism 
Although some drugs are excreted unchanged in the urine, most drugs have to be 
metabolized to more water soluble molecules before being excreted. Metabolism can be 
divided into phase I and phase II. In phase I, the drug is oxidized, reduced, or 
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hydrolyzed into, usually, a pharmacologically inactive substance. In phase II, the drugs 
are conjugated with other more water soluble molecules such as a glucuronide, or an 
acetyl group. Some substances do not undergo phase I metabolism, and they are only 
conjugated before excretion. Others are only metabolized by phase I enzymes before 
excreted. Most of the metabolism occurs in the liver, although other tissues also have 
some capacity to metabolize drugs.  
 
1.2.4.1 Phase I metabolism 
Phase I metabolism is predominately catalyzed by cytochrome P-450 enzymes. Among 
these, CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 are the most important 
enzymes involved in drug metabolism and will thus be further discussed. For each 
enzyme examples of substrates, inducers and inhibitors are given. 
 
CYP1A2 is responsible for the metabolism of e.g. clozapine [32], caffeine [33;34], and 
theophylline [35]. CYP1A2 is also responsible for the metabolism of amines from 
tobacco smoke and fried food into reactive procarcinogens [36]. Smoking, intake of 
barbequed food, and broccoli may induce the expression of CYP1A2 [37]. The enzyme 
is also induced by drugs such as carbamazepine [38], and rifampicin [39]. Examples of 
inhibitors of CYP1A2 are ciprofloxacin [40] and fluvoxamine [38]. 
 
CYP2C9 mainly metabolizes weakly acidic drugs such as warfarin [11], diclofenac 
[41] and tolbutamide [9]. Rifampicin is an inducer of CYP2C9 [42], and examples of 
inhibitors are fluconazole [43], fluvastatin [44], and sulfamethoxazole [45]. 
 
CYP2C19 metabolizes many drugs to a small extent, but some of the drugs that are 
extensively metabolized by this enzyme are omeprazole [46], diazepam [47], and 
citalopram [48]. Example of inducers are rifampicin [49],  and St John’s wort [50]. 
Omeprazole [51] and fluvoxamine [52] are inhibitors of this enzyme. 
 
CYP2D6 metabolizes codeine into the active metabolite morphine [53]. Other 
substrates of CYP2D6 are haloperidol [54], and metoprolol [55]. CYP2D6 appears not 
to be inducible, although activity is increased in pregnancy [56]. Fluoxetine [57], 
quindine [58;59] and bupropion [60;61] are all inhibitors of CYP2D6.  
 
CYP3A4 is the cytochrome that is most important for metabolism of drugs and it 
metabolizes more than 50% of all drugs on the market [62]. CYP3A4 is expressed 
mainly in the liver, but also to a relevant extent in the gut. Midazolam is used as a 
probe drug for CYP3A4 activity in drug interaction studies [22;23;63]. Other substrates 
are e.g. simvastatin [64], quetiapine [65], and sildenafil [66]. CYP3A4 can be induced 
by enzyme inducing anticonvulsants (carbamazepine [67], phenobarbital [68], 
phenytoin [69], rifampicin [70], St John’s wort [71], and efavirenz [72]. Inhibitors of 
CYP3A4 usually cause a significant increase in the concentration of substrates, 
especially those with a low bioavailability. Examples of inhibitors are HIV protease 
inhibitors [73], azole antifungals [74], erythromycin [75], and clarithromycin [76]. 
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CYP Substrates Inducers Inhibitors 
CYP1A2 clozapine  
theophylline 
carbamazepine 
rifampicin 
ciprofloxacin 
fluvoxamine 
CYP2C9 warfarin 
diclofenac 
tolbutamide 
rifampicin 
 
fluconazole 
fluvastatin 
sulfamethoxazole 
CYP2C19 omeprazole 
diazepam 
citalopram
rifampicin 
St John’s wort 
omeprazole 
fluvoxamine 
CYP2D6 codeine 
haloperidol 
metoprolol 
no known fluoxetine 
quinidine 
bupropion 
CYP3A4 midazolam 
simvastatin 
quetiapine 
sildenafil 
rifampicin 
carbamazepine 
phenytoin 
phenobarbital 
St John’s wort 
ritonavir 
erythromycin 
ketoconazole 
Table 1. Some examples of substrates, inducers and inhibitors of certain CYPs. 
 
1.2.4.2 Phase II metabolism 
The enzymes involved in phase II metabolism are called transferases, and they add 
chemical groups to drug molecules to make them larger and more water soluble. The 
enzymes involved are sulfonyltransferases adding a sulfate, UDP-
glucuronyltransferases (UGT) adding glucuronic acid, glutathione-S-transferases 
adding glutathione, N-acetyltransferases adding an acetyl group, and methyltransferases 
adding a methyl group [1;62]. 
 
Many drugs are glucuronidated by UGTs before being excreted. Most glucuronidation 
occurs in the liver. Glucuronidation may occur by addition of a glucuronic acid 
molecule directly to the mother substance, or the glucuronide may be added to a 
metabolite of the mother substance. Most glucuronides are pharmacologically inactive, 
but there are examples of active molecules such as morphine-6-glucuronide, which is 
actually more potent than its mother compound [77]. UGTs have been shown to be 
inducible by drugs such as ritonavir [78] and rifampicin [79].  Example of substrates, 
inhibitors and inducers of UGTs are presented in table 2. Valproic acid is a known 
inhibitor of several UGTs, such as UGT1A4, UGT2B7 and UGT2B15 [80]. 
Glucuronidation is, in general, less investigated than CYP-mediated metabolism. Many 
drugs are substrates of several UGTs, and there is still much about glucuronidation that 
is unknown.  
 
It is known that drugs are substrates of other phase II enzymes, but information about 
interactions involving these enzymes are lacking. 
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 Substrates Inducers Inhibitors 
UGT1A1 ezetimibe [81]  
etoposide [82] 
SN-38 (active metabolite 
of irinotecan)[83;84]
flavonoids [85] 
phenobarbital [86] 
efavirenz [87] 
gemfibrozil [88] 
atazanavir [89] 
UGT1A3 telmisartan [90] 
lamotrigine[91] 
 gemfibrozil [92] 
UGT1A4 lamotrigine [91]  
olanzapine[93] 
carbamazepine [80] valproic acid [80] 
efavirenz [94] 
UGT1A6  paracetamol [95] 
 
carbamazepine [92]  
UGT1A9 R-oxazepam [80] 
etodolac [96] 
propofol [97] 
phenobarbital [97] 
rifampicin [97] 
efavirenz [94] 
UGT2B7 epirubicin [98] 
morphine [99] 
zidovudine [100] 
phenobarbital [92] valproic acid [101] 
fluconazole [102] 
UGT2B15 lorazepam [103] 
S-oxazepam [104]
phenobarbital [92] valproic acid [101] 
Table 2. Some examples of substrates, inducers and inhibitors of certain UGTs. 
 
1.2.5 Pharmacogenetics 
The effect of drugs can vary greatly from patient to patient, and this can at least partly 
be explained by genetic differences. These differences may be due to alterations in the 
gene encoding for the drug target, making the effect of the drug more or less 
pronounced or even make the drug totally ineffective. One example of this is 
polymorphisms in the β2-receptors that have been associated with decreased efficacy in 
asthma treatment [105]. Another example when pharmacogenetics is important is when 
treating breast cancer with trastuzumab. For the drug to be effective the tumors have to 
overexpress HER2 proteins and patients are genotyped before treatment [106].  
 
Alteration in the genes coding for drug metabolizing enzymes and drug transporters, 
may dramatically alter patients’ exposure to drugs. Genetic polymorphisms may result 
in expression of an enzyme with decreased or increased capacity to metabolize 
substrates, and for some enzymes it may result in a non-functional enzyme. The 
prevalence of certain polymorphisms differs greatly between ethnic populations.   
 
Genetic polymorphisms in the gene encoding for P-gp have been found and linked to 
level of exposure to some HIV drugs, efficacy of certain chemotherapeutics, and effect 
of some antidepressants [107;108].    
 
CYP2D6 is the most studied enzyme regarding alteration in drug exposure due to 
genetics. There are more than 100 genetic alterations found within the CYP2D6 gene 
[109]. The alterations can result in decreased efficacy when metabolizing drugs or, as 
in the case of CYP2D6, some polymorphisms may lead to a non-functional enzyme. 
Increased CYP2D6 activity in patients has also been reported, and it has been shown to 
be caused by gene duplications. The concentration of a CYP2D6 substrate such as 
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nortriptyline, may vary greatly among individuals receiving similar doses. The 
exposure to nortriptyline have been shown to be  332% higher in poor metabolizers (no 
functional allele) and 79% lower in a patient with 13 gene copies, when compared to 
extensive metabolizers having two functional alleles [110].  
 
CYP2C9 is another polymorphic enzyme with two polymorphisms, *2 and *3, that are 
relatively common in a Caucausian population (allele frequency *2 11-16%, and *3 7-
10%) [111]. CYP2C9 is the enzyme responsible for metabolism of the active S-
enantiomer of warfarin and it has been shown that patients with one *2 allele require 
20% lower warfarin maintenance doses, patients with one *3 35% less, and in patients 
with two *3 alleles the maintenance dose is approximately 78% lower [112]. Mutations 
in the CYP2C9 gene significantly increases the risk for bleeding during the first two 
weeks of treatment with warfarin [113]. No non-functional polymorphisms have been 
reported for the CYP2C9 enzyme. 
  
Other cytochrome P-450 enzymes with important polymorphisms are CYP2C19 and 
CYP3A5 where mutations can lead to non-functional enzymes. 
 
Several polymorphisms have been found in the genes coding for UGTs. UGT1A1 is 
responsible for glucuronidation of bilirubin and genetic differences are the cause of 
Gilbert’s disease [114]. This disease causes intermittent hyperbilirubinemia. It has been 
shown that patient with Gilbert’s disease are more prone to adverse effects when 
treated with irinotecan, due to decreased elimination of the active SN-38 metabolite 
[115]. Otherwise, little information is available regarding the influence of certain UGT 
mutations on the exposure to drugs. Since there is a great overlap in substrates and 
many polymorphisms are co-inherited, the effect of certain polymorphisms on 
glucuronidation is difficult to study [80]. 
 
1.2.6 Therapeutic drug monitoring 
Therapeutic drug monitoring is used to optimize drug therapy by measuring drug 
concentration in patients. The method was introduced in the early seventies, and is used 
for drugs with narrow therapeutic interval such as digoxin [116]. A patient’s drug 
concentration is measured to identify if it is within the therapeutic interval. Today, 
more than a hundred substances are routinely measured at the clinical pharmacology 
laboratory at Karolinska University Hospital. Some of the most common analyses are 
those of aminoglycosides, to limit the risk for oto- and nephrotoxicity, of antipsychotics 
and antidepressants, to optimize therapy, and of immunosuppressant drugs to prevent 
organ rejection and decrease the risk for adverse effects. 
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1.3  DRUG INTERACTIONS  
1.3.1 Drug interaction – definition  
A drug interaction occurs when the effect of one drug is altered by another drug, food, 
or herb. The result can be increased effect, adverse effects, reduced effect, or a total 
lack of effect of the drug which action is altered. Drug interactions can be divided into 
pharmacodynamic interactions and pharmacokinetic interactions.  
 
1.3.2 Pharmacodynamic interactions 
Pharmacodynamic interactions occur when the effect of a drug is altered due to another 
drug without any alteration in pharmacokinetics. Interactions can be additive when e.g. 
two drugs are agonists of the same receptor, and concomitant use causes an increased 
effect and also an increased risk for adverse effects. One example of an additive 
pharmacodynamic interaction is concomitant use of MAO-inhibitors and serotonin 
reuptake inhibitors (SSRIs). SSRIs block the reuptake of serotonin in synapses and 
monoamino oxidase degrades serotonin in the synapses. When both the uptake and 
degradation of serotonin is inhibited, the synaptic concentration of serotonin increases 
dramatically and this causes overstimulation of serotonin receptors [117]. The clinical 
symptoms of serotonin syndrome are tremor, myoclonus, confusion and agitation. In 
worst case, serotonin syndrome may cause hyperthermia and muscle rigidity which 
may be fatal [118]. Other combinations of serotonergic drugs may also cause serotonin 
syndrome [117].  
 
Another example of a pharmacodynamic interaction is the one between SSRIs and non-
steroidal antiinflammatory drugs (NSAIDs). Both drug classes increase the risk for 
gastrointestinal hemorrhage and the risk is increased up to 6-fold when they are co-
administered [119].Classical agonist-antagonist interactions are also classified as 
pharmacodynamic interactions. One example is less effect of beta-stimulants for 
asthma treatment in patients using unselective beta blockers. Another example is 
reduced effect of warfarin when patients treated with warfarin ingest large amounts of 
vitamin K. 
 
1.3.3 Pharmacokinetic interactions 
Pharmacokinetic interactions may change the exposure to the drug causing increased 
effect, adverse effects, or absence of effect.  Pharmacokinetic drug interactions may 
involve absorption, distribution, transport, metabolism, or excretion (renal or fecal) of 
the drug (see figure 1).  
 
Absorption interactions can occur when e.g. the drug binds to cations. For example 
when doxycycline is co- administered with magnesium ions, doxycycline binds to 
magnesium forming a salt that cannot be absorbed. The uptake of doxycycline is 
decreased significantly, and the combination may lead to lack of antibiotic effect [120]. 
Absorption interactions can also be due to alteration in gastric pH. One example is the 
HIV protease inhibitor atazanavir, which needs a low pH to be sufficiently absorbed. If 
a proton pump inhibitor is given, the exposure to atazanavir decreases by 62-94% 
[121;122] and this may result in reduced antiviral activity.  
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Distribution interactions occur mainly due to competitive binding to plasma proteins. 
This interaction may occur when two drugs that are highly bound to the same plasma 
protein are co-administered. This type of interaction gives an increase in free fraction of 
the drugs, which may cause adverse effect if they have narrow therapeutic intervals. 
One example of such drug is phenytoin and interactions with acetylsalicylic acid 
[123;124], and valproic acid [125] have been reported. These interactions often lack 
clinical significance since they usually are transient. 
 
 
 
 
Figure 1. Pharmacokinetic drug-drug interactions can occur at different 
places within the body. Some occur in the gastrointestinal system, other in the liver or 
in the kidneys. 
 
Interactions involving transport can increase or decrease the effect of drugs. An 
example of a drug interaction at transporter level is the interaction between digoxin and 
verapamil [126], where inhibition of P-gp by verapamil [127] increases the plasma 
concentration of digoxin. Another example is the interaction between ciclosporin and 
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atorvastatin [128], where ciclosporin inhibits the transport of atorvastatin by OATP1B1 
[129]. This results in decreased uptake of atorvastatin into liver cells, and thereby 
decreased metabolism and increased statin concentrations. 
 
Metabolic interactions are usually caused by either inhibition or induction of a 
metabolic pathway. CYP mediated interactions have been well studied and much 
knowledge is available. One of the most pronounced CYP interactions is between 
lopinavir/ritonavir and tacrolimus, where the tacrolimus dose may have to be reduced 
by 99% [130] due to inhibition of CYP3A4. Induction of CYP enzymes can also cause 
dramatically decreased drug concentration. For example, rifampicin reduces the 
bioavailiability of nifedipine by 88% [131] and decreases S-warfarin exposure by 75% 
[132]. 
 
Interactions can also occur due to inhibition or induction of UGTs. Valproic acid is a 
known inhibitor of several UGT enzymes, and clinically relevant interactions occur 
with UGT substrates such as lamotrigine [133;134] and mycophenolic acid [135]. 
Induction interactions have been reported between lamotrigine and inducers such as 
rifampicin [79] and carbamazepine [134]. Much is still unknown regarding drug 
interactions caused by inhibition or induction of UGTs.  
 
Drug interactions involving urinary excretion can occur when for example one drug 
changes the pH of urine causing less excretion of the other drug. Changes in renal 
blood flow can also change the excretion of drugs.  NSAIDs can decrease renal blood 
flow and this may cause increased concentration of lithium [136], which is excreted in 
unchanged form in urine.  
 
1.3.4 Drug interactions with food or natural remedies 
Some drugs may interact with food. Calcium containing products such as milk and 
yoghurt may, by chelate formation, decrease the uptake of tetracyclines and 
fluoroquinolones. The uptake of ciprofloxacin may be lowered by approximately 30-
40% [137] which may result in therapeutic failure.   
 
Grapefruit juice has been shown to be a potent inhibitor of CYP3A4 [138] and P-gp 
and ingestion may cause dramatic increases in the concentration of drugs that have low 
bioavailiability such as nifedipine [139].  The interaction is mostly due to inhibition of 
intestinal CYP3A4 and P-gp [138]. Other fruit juices may also influence the 
pharmacokinetics of drugs. Orange juice can decrease bioavailiability of atenolol [140] 
and pomegranate juice has in a few cases been shown to increase the effect of warfarin 
[141]. 
 
Natural remedies can also cause clinically important drug interactions. St John’s wort is 
a potent inducer of CYPs and concomitant use may cause pronouncedly decreased 
concentrations of other drugs. Many pregnancies have been reported due to lack of 
effect of oral contraceptives [142]. Other herbs such as ginkgo biloba [143], and 
ginseng [144] also interact with drugs.  
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Smoking is a life style factor that may have great influence on drug therapy. Smoking 
induces CYP1A2 and e.g. clozapine exposure is about 40% lower in smoking patients 
[145]. 
 
1.3.5 Evaluation of drug interaction studies 
Drug interactions can be studied in many ways. In vitro system using human liver 
microsomes give information about which enzymes that may be involved in the 
metabolism of a drug. Results from in vitro studies should be used as an indication of 
interaction but not as evidence of an interaction.  
 
Many drug interaction studies are performed as cross-over studies in healthy 
volunteers. Results from these studies give valuable information about drug interactions 
in general. There are, however, some limitations to this kind of studies. The number of 
study subjects is usually small, and inclusion of a single patient with different genotype 
or some other reason for altered pharmacokinetics may influence the result. It is also 
important that the doses used are the same as therapeutic doses, since pharmacokinetics 
may be different using other doses. The length of drug administration may also be 
important and steady-state data is often aimed for. If induction is studied the length 
should, ideally, be long enough to reach maximum induction and a new steady-state. 
 
Drug interactions may be studied using data from TDM databases. Interactions are 
studied by comparing concentration/dose ratios among exposed versus unexposed 
patients. When evaluating these studies one should bear in mind that patient data in a 
TDM material may not be representative for all patients since TDM is often used when 
problems occur. However, using TDM data may also have benefits since the 
measurements are made in patients and not in healthy volunteers, thus it could be more 
representative for the users of the drugs.  
 
1.3.6 Polypharmacy and interactions 
The more drugs a patient uses the more likely is the risk of being exposed to drug-drug 
interactions. When concomitant drugs interacting in several ways are co-administered 
the net result of an interaction is difficult to assess and it can also differ among patients 
due to environmental and genetic factors.  
 
For many drugs, metabolism may be dependent on more than one CYP, and if one of 
the CYPs is inhibited no clinically relevant interaction may be observed, but if the other 
path also is inhibited the patient might be exposed to a significant interaction. For 
example, oxycodone is metabolized by both CYP3A4 and CYP2D6. Inhibition of one 
of the enzymes does not cause a clinically significant change in the effect but inhibition 
of both enzymes may cause dramatically increased concentration [146], which may 
cause respiratory depression. Such a case could easily occur for example in a patient 
treated with fluoxetine, inhibiting CYP2D6 [57], for depression and started on 
erythromycin, inhibiting CYP3A4 [75], for treatment of a respiratory infection.   
 
 12 
 
1.3.7 Pharmacogenetic differences 
Pharmacogenetics may also influence the occurrence of drug interactions. In the case 
of oxycodone the drug effect is not significantly altered in poor metaboliser of 
CYP2D6 but if a CYP3A4 inhibitor is co-administered the concentration will increase 
dramatically [146].  
 
If an inhibitor of CYP2D6 is given to a poor metaboliser, the concentration of a 
CYP2D6 substrate will not be altered [147],  since the patient does not have any 
CYP2D6 that can be inhibited.  The same is true for CYP2C19 and one such example 
is the interaction between diazepam and omeprazole. Omeprazole increases the 
concentration of diazepam in extensive metaboliser of CYP2C19 whereas no 
significant change is observed in poor metabolisers [51]. 
 
 
1.4 DRUG INTERACTIONS – OCCURRENCE AND CLINICAL 
RELEVANCE 
1.4.1 Prevalence of drug interactions 
Drug use has increased steadily since more drugs have entered the market and also 
because the population tends to get older and older. Between 2005 and 2008, the total 
drug use (defined as number of drugs during 3 months) per patient in Sweden increased 
by 3.6 % and the total prevalence of polypharmacy (patients with five or more drugs) 
increased by 8.2%. The number of patients exposed to 10 or more drugs increased by 
15.7% [148]. Another, older Swedish study revealed that the number of drugs used by 
patients 77 years or older had increased from 2.5 to 4.4 between 1992 and 2002, while 
the prevalence of polypharmacy in this age group increased 3-fold (from 18 to 42%) 
[149]. 
 
The risk for drug interactions increases dramatically by the use of more drugs.  
Theoretically, the maximal number of potential drug-drug interactions in an individual 
patient can be described by this formula: 
 
݊ݑܾ݉݁ݎ	݋݂	݀ݎݑ݃ݏଶ െ ݊ݑܾ݉݁ݎ	݋݂	݀ݎݑ݃ݏ
2  
 
For example, a patient using three drugs may in worst case be exposed to three 
interactions. A patient using five drugs may have ten interactions, and a patient using 
ten drugs may, at least theoretically, be exposed to 45 drug interactions. Increases in 
polypharmacy may therefore greatly increase the prevalence of drug-drug interactions. 
Of course, it is almost impossible that every drug used by a patient on 10 drugs would 
interact with every other drug but it shows that the potential for interactions is 
increasing non-linearly. In one study, investigating drug interactions in the emergency 
department, the risk of a potential drug interaction was 13% among users of two drugs 
and it was as high as 82% among patients using seven or more drugs [150].  In another 
study investigating CYP mediated drug interactions among patients on polypharmacy 
the probability of at least one drug interaction was calculated. The risk was 50% in 
patients using 5-9 drugs, 81% in those using 10-14 drugs, 92 % in those with 15-19 
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drugs and 100% in patients using more than 20 drugs [151].  In a Dutch study the 
prevalence of drug interactions in patients aged 70 or older was increased from 10.5% 
to 19.2% between the years 1992 and 2005. The prevalence of serious drug interactions 
(potentially life threatening) almost doubled from 1.5% to 2.9% [152].  
 
Many studies have investigated the prevalence of potential drug interactions based on 
prescription data and figures ranging from 6 to 89% have been reported [153]. Data 
from this kind of studies are almost impossible to compare since the definition of 
potential drug-drug interactions often are is differently classified, and a DDI classified 
as severe in one database might be classified as of minor importance in another 
database or is completely missing. The source has great influence on the number of 
interactions found since some drug interaction databases only includes a small number 
of drug-drug interactions whereas others may include many more e.g. Swedish Finnish 
Interaction X-referencing (SFINX) can today identify more than 17 000 drug-drug 
interactions.  In a yet unpublished study based on all dispensed drugs in Sweden during 
4 months, the total number of interacting drug combinations according to SFINX were 
>2 000 000. The prevalence of C and D interactions were (n >900 000), and  (n = >90 
000) respectively [154]. In the end of 2013 there were around 9.6 million people living 
in Sweden [155].  
 
Of more interest are studies investigating actual drug-drug interactions that have caused 
some kind of clinical problem and lead to hospitalization or emergency department 
visits. In a large review of published studies the overall incidence of drug-drug 
interaction resulting in emergency department visits was 0.054 %, and 0.57% for 
hospitalizations. However, in elderly patients drug-drug interactions were assumed to 
be the cause of 4.8% of admissions [156]. In general the risk of adverse drug 
interactions leading to hospital admission seems to be low but several studies suggest 
that it is much more common in elderly patients than in younger. This is in line with the 
increased number of drugs used by the elderly. They may also be more prone to drug 
interactions due to for example decreased renal function exposing them to higher drug 
concentrations. In some patient groups such as HIV-patients, patients using 
anticonvulsants and patients on chemotherapy the risk for hospitalization is probably 
higher due to use of interacting drugs with narrow therapeutic intervals.  
 
1.5 CLINICAL DECISION SUPPORT SYSTEMS 
In the information age we live in, the problem usually is not to find information but 
rather to grasp only the most important information. Increasing knowledge about 
treatment options, new guidelines, new drugs and more specific drug information 
makes it almost impossible for health care personnel to keep up with and have 
everything available when needed. To guide prescribers and pharmacists when making 
decisions on how to handle e.g. patients’ drug treatment, clinical decision support 
systems (CDSSs) have been developed. A CDSS is a system that, optimally, uses 
patient specific data to give the user case specific advice. CDSS can give users 
immediate information about e.g. duplicated drug treatment, drug-drug interactions, 
drug use in pregnancy and overdosing when prescribing. CDSSs are used to decrease 
errors, increase patient safety, improve health care and save time.  
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CDSSs are based on knowledge bases providing information. The quality of the 
knowledge base is one of the factors determining the usefulness and trustworthiness of 
a CDSS. Information in a knowledge base should be structured in a way that it easily 
can be integrated into an electronic health care record system or into a dispensing 
system at the pharmacy. It should be possible to link patient specific data such as e.g. 
patients complete drug list, age, sex, kidney function through various algorithms to the 
database. Knowledge bases can also be provided through a website where the patient 
linkage is missing.  
 
Knowledge bases in CDSSs should, ideally, be evidence based and developed in close 
collaboration between experts within the area, software developers and potential users 
of the system.  
 
1.5.1 Drug-drug interaction warning systems 
Drug-drug interactions warning systems are commonly used in CDSSs. When used, 
they warn the prescribers or pharmacists when prescribing/dispensing interacting drugs. 
For example, when a prescriber initiate treatment with a new drug this drug is checked 
against all the drugs that the patient is already using and drug-drug interaction 
information is then presented. In some systems the alerts are intrusive, forcing the user 
to read them and the system may even require provision of a reason if the user 
overrides the warning. In other systems warnings are shown in a non-intrusive manner. 
Color coding may also be used to hint about the seriousness of the warning. Some drug 
interaction warning systems, such as SFINX [157] and Stockley’s Interactions Alert 
[158], are available both in a web version and integrated into electronic health care 
records.  
 
Interaction texts should be structured to improve readability and make integration into 
electronic health care records easier. Background information including references is 
useful and strengthens the evidence for the specific interaction. This increases the 
perceived trustworthiness of the source. 
 
Usage of drug-drug interaction warning systems can in some instances decrease 
prescribing of interacting drugs [159], but studies showing evidence of clinical benefit 
is lacking  [160]. Unfortunately, drug-drug interaction warning systems are often not 
used optimally. Limitations are mainly due to over-alerting. Many systems give the 
user too many warnings and/or warnings that are irrelevant for the patient the physician 
is treating. This makes the user annoyed and less likely to care about the warnings 
shown. Irrelevant warnings may also occur due to bad implementation e.g. warnings 
may be given due to old prescriptions that are still stored in the patient’s medication list 
[161]. 
 
Not much is known about the dangers of overriding alerts. A Dutch study investigated 
how often ECG was taken in patients after the prescriber had overridden a warning 
about risk for QT-prolongation. They found that in 33% of the patients an ECG was 
taken within a month after initiation of concomitant therapy. Among patients with ECG 
taken before and after treatment initiation, 31% had an increase in QTc-interval 
increasing the risk for torsade de pointes [162]. This indicates that overriding of QT 
warnings may, theoretically, lead to significant QT-prolonging in many patients.  
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Classification of interaction according to severity is beneficial in increasing alert 
acceptance among prescribers [163] and preferred by users [164]. The classification 
system makes it possible to tailor the system better by displaying the warnings in 
different ways due to severity.  This has been shown to decrease the problem with over-
alerting. Also the signal to noise ratios are often poor [165] and many of the warnings 
are overridden by the users. Another feature that users prefer is recommendations on 
how to handle interactions [166;167]. These recommendations should be clear and as 
general as possible.  
 
The quality of drug-drug interaction warning systems has been questioned. 
Comparisons have shown that even among the most severe warnings there coverage 
varies greatly between different sources [165;168]. This can be due to inclusion criteria 
for a database (e.g. exclusion of certain pharmacodynamic interaction), but there could 
also be other reasons such as non-critical inclusion of all interactions mentioned in the 
product information.  
 
One should always remember that even if an almost perfect drug-drug interaction 
warning systems gives useful information, the decision on how to handle the specific 
patient should always be made by the prescriber. There may be cases where serious 
drug-drug interactions are intended and beneficial or drug treatment is absolutely 
necessary. The system may also give recommendations that are not useful for each 
patient since recommendation texts are written for the most common indication of a 
drug.  
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2 AIMS 
The main aim of this thesis was to design and create a drug-drug interaction database, 
suitable for integration into clinical decision support systems, to evaluate the user 
satisfaction with the knowledge base and its effects on prescribing habits with respects 
to potentially serious drug interactions, and to use previously collected data to find new 
valuable information regarding specific drug interactions. 
 
The specific aims of the included studies were: 
 
Study I: To develop a drug-drug interactions database especially optimised for 
inclusion in a clinical decision support system. 
 
Study II: Use data from our therapeutic drug monitoring database to investigate the 
possible interaction between lamotrigine and quetiapine. 
 
Study III: Use data from the Warfarin genetics study (WARG) to study if the 
interaction between warfarin and simvastatin is dependent on genetic variations in the 
metabolism of warfarin. 
 
Study IV: To evaluate how the drug interaction database SFINX is perceived, and to 
measure the usage among users of the web version. 
 
Study V: To study the influence of integration of SFINX, as a clinical decision support 
system, on the prevalence of prescription of potentially serious drug-drug interactions. 
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3 METHODS 
3.1 STUDY POPULATIONS 
Study II was based on data from the routine therapeutic drug monitoring service 
database at Clinical Pharmacology at Karolinska University Hospital. The database 
holds information about all drug measurements since 1991 and is a valuable resource 
for drug interaction studies. Data were used to identify patients exposed to quetiapine 
with or without concomitant lamotrigine. Information about drug concentration, dose, 
sampling time, dosage form used and other concomitant drug was retrieved for all 
patients included in the study. 
 
In study III, we used data from the WARG study [169], a prospective cohort study with 
the aim of identifying risk factors for adverse outcome of warfarin therapy. The cohort 
consisted of 1523 patients. All these patients were genotyped for genes important for 
warfarin effect such as CYP2C9 and vitamin K epoxide reductase subcomplex 1 
(VKORC1). Other medications used were also registered.  In study III, we extracted all 
patients who had used simvastatin and warfarin simultaneously and compared them 
with all other patients within the cohort. 
 
In study IV, an e-mail invitation to answer a questionnaire about SFINX was sent out to 
all registered users (n=11763) of the web version of SFINX (available at http://www. 
janusinfo.se).  Among these users most are health care personnel and pharmacists but 
anyone in Sweden can register as a user and many student, patients and relatives are 
registered. Since the major aim of the study was to investigate the use of SFINX by 
prescribers and pharmacist only answers from physicians, midwives, dentists, nurses 
with prescribing rights and pharmacists were included in the analysis. 
 
In study V, we contacted the head of each primary health care centers (n=26) in the 
northwestern part of Stockholm County. Some of the centers started using SFINX in 
February 2007 (SFINX group), integrated into their electronic health record system, 
and some did not have any electronic drug interaction warning system (control group).  
Twenty of the primary health care centers agreed to participate in the study. Thereafter 
we retrieved data from the Swedish Prescribed Drug Register on all prescription from 
these health care centers for the two time periods September to December 2006 and for 
the same months 2007. In total we had data on 90 806 prescriptions during 2006 and 
91 489 prescriptions in 2007. Among these approximately 19% were in the control 
group and the rest were in the SFINX group. In the SFINX group we had data from 
approximately 20 000 patients in each period and in the control group we only had data 
from around 5000 patients per period.  The patients had a median age of 58 in each 
group with an interquartile range of 40 or 41 to 70 or 71 indicating that the groups were 
rather similar. The gender distribution was also similar in all groups with 39-40% men.  
 
All studies based on patient data (II, III, and V) were approved by the Regional Ethics 
Committee.  
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3.2 SWEDISH PRESCRIBED DRUG REGISTER 
The Swedish Prescribed Drug Register is a register of all dispensed drugs in Sweden 
[170]. It was started in July 2005 and is held by the Swedish National Board of Health 
and Welfare. The register contains information about drugs prescribed, date of 
prescription and dispensing, profession and workplace of the prescriber, the age, 
gender, place of residency and personal number (unique identifier) of the patient. The 
register does not hold information about drugs given in hospital or drugs purchased 
over the counter. The use of personal identity numbers in the register is valuable for 
research since it makes it possible to link this register with other registers such as the 
register of in-patient care or the register of deliveries.  
 
3.3 STATISTICAL METHODS  
For descriptive data median and interquartile ranges were calculated.  Proportions were 
compared using Fishers exact test (study V). T-test was performed to analyze 
differences in a continuous variable between two groups (study III) 
 
Multiple linear regression was used to analyze effect of different variables on a 
continuous variable (Study III) and logistic regression was used to analyze the effect on 
binary variables (study V). 
 
Mann-Whitney U test was used to compare grouped, continuous non-normally 
distributed data (study II). For paired analyses of continuous non-normally distributed 
data, and ordinal data, Wilcoxon signed rank test was used (Study II, study IV).  
 
Spearman rank correlation was used to investigate correlation between two non-normal 
distributed continuous variables and also between two ordinal variables (study II, study 
IV).  
 
All tests were two sided and p<0.05 was considered as statistically significant. All 
statistical analyses were performed using R [171].   
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4 RESULTS 
The designs are only briefly described and only the main findings are presented in this 
chapter of the thesis. Further information is available in the published papers and in the 
manuscript (paper IV).  
 
 
4.1 STUDY I 
4.1.1 Design 
This study describes the concept of the SFINX knowledge base. SFINX was built in 
collaboration between Karolinska Institutet, Stockholm County Council and Turku 
University. Important steps in building the database were handling of substances, e.g. 
the development of the mother-child concept for salts, handling of their formulations, 
classification of interactions, standardization of texts, development of standard 
operating procedures and the process of text writing and approval.  
 
4.1.2 Results 
The result of this work is a database used both in Sweden and Finland. SFINX is 
incorporated in health record systems in both countries and is also available as a web 
solution in both countries. At the time of manuscript writing the database consisted of 
more than 8000 interaction drug pairs and more than 31 000 pharmacists and 
physicians were using the database. The texts are structured into four parts, 
consequence, recommendation, mechanism and background. An example of an 
interaction text found in SFINX is shown in figure 2. All background text have 
numbered references showing the scientific evidence of the interaction. The 
consequence and the recommendation texts are translated to Swedish and Finnish and 
they appear at first when SFINX is used in the portal version and in electronic health 
care records.  
 
A “read more” link is shown for users who want more information about the 
interaction. The database considers drug dosage form and thereby the noise due to 
unnecessary warnings is limited. All interactions are classified from A to D according 
to their clinical relevance and from 0 to 4 according to the level of documentation.  
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Figure 2. Example of an interaction text in SFINX. The consequence and 
recommendation texts are translated into Swedish and Finnish. 
 
 
4.2 STUDY II 
4.2.1 Design 
Study II was a case-control study investigating the interaction between quetiapine and 
lamotrigine. All subjects exposed to quetiapine were extracted from the TDM database 
(n=422). Among these, 22 had received concomitant therapy with quetiapine and 
lamotrigine. These patients were matched for gender, age and dosage form of 
quetiapine with 22 patients unexposed to lamotrigine. Concentration/dose (C:D) ratio 
was compared between patients exposed and unexposed to lamotrigine both in a paired 
analysis and in an unpaired analysis. The effect of lamotrigine exposure on the 
quetiapine C:D ratio was also analyzed. 
 
4.2.2 Results 
The mean C:D ratio of quetiapine was found to be significantly lower in subjects co-
treated with lamotrigine (0.71, 95% C.I. 0.46-0.97) compared to the C:D ratio in their 
corresponding controls (1.64, 95% C.I. 1.00-2.28) p=0.013. Figure 3 shows the 
difference in C:D ratio between cases and controls. Quetiapine concentration (dose-
corrected) was 58% lower in patients co-treated with quetiapine and lamotrigine. We 
did not find any correlation between lamotrigine exposure and quetiapine C:D ratio.   
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Figure 3. Difference in quetiapine C/D ratio (μmol/L)/(mg/d) between cases (co-treated 
with lamotrigine and quetiapine) and matched controls (unexposed to lamotrigine). 
Each bar illustrates the difference between the C/D ratio of an individual case and its 
corresponding matched control. Negative values indicate a lower C/D ratio in the 
lamotrigine-exposed individual. 
 
 
4.3 STUDY III 
4.3.1 Design 
Data from the WARG study was used to analyze if polymorphisms in the CYP2C9 
gene influence the magnitude of the interaction between warfarin and simvastatin. 
Patients who had received warfarin for at least 28 days, not using other drugs that alters 
INR and successfully genotyped for CYP2C9 were included in the study. To be 
included in the simvastatin group the patients should have received warfarin and 
simvastatin concomitantly for at least 28 days. The median weekly warfarin dose 
during 90 days of therapy (starting 15 days after initiation of treatment) was calculated 
for each patient. If the patient had not received warfarin for 90 days all days on 
warfarin was included. In the simvastatin group the median weekly dose was calculated 
from day 15 on concomitant therapy. In the primary analysis we compared the warfarin 
dose in patients using simvastatin with patient not using simvastatin. To analyze the 
impact of genotype on the interaction we did a multiple regression including an 
interaction between genotype and simvastatin use. 
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4.3.2 Results 
The number of patients who met the inclusion criteria was 1132 where 143 were 
included in the simvastatin group and the remaining 989 were included in the control 
group. In all patients, usage of simvastatin was associated with an 8% lower weekly 
warfarin dose (p=0.045).  In patients carrying at least one CYP2C9*3 allele the 
warfarin maintenance does was significantly lower, -21.4%, if treated with simvastatin. 
When using multiple regression to adjust for other factors we found no significant 
effect of simvastatin on the warfarin dose requirement except for in patients with 
CYP2C9*3 alleles. According to the model a patient with one *3 allele should have a 
25% lower dose when co-treated with simvastatin and a patient with two *3 alleles 
should have their dose decreased by 43%. Results from multiple regression are 
presented in table 3. 
 
  Beta Effect on warfarin 
dose 
p-value 
Age -0.012 (-0.013 to -
0.010) 
- 1.2 %  (-1.33 to -
1.03) 
< 0.0001 
Male sex 0.103 (0.059 to 
0.146) 
 10.8 % (6.08 to 
15.72)
< 0.0001 
Simvastatin 0.018 (-0.056 to 
0.092)  
1.8 % (-9.64 to 5.41) ns 
No. of CYP2C9*2 alleles  -0.203 (-0.252 to -
0.153) 
 -18.3 % (-22.28 to -
14.19) 
< 0.0001 
No. of  CYP2C9*3 alleles   -0.384 (-0.445 to -
0.323)
-31.9 % (- 35.91 to - 
27.62)
< 0.0001 
Interaction Simvastatin × *2 -0.032 (-0.161 to -
0.096) 
-3.2 % (-14.85 to 
10.13) 
ns 
Interaction Simvastatin × *3  -0.281 (-0.447 to -
0.115) 
 -24.5 % (-36.08 to -
10.86) 
0.0009 
Table 3. Results from multiple regression. 
4.4 STUDY IV 
4.4.1 Design  
Study IV presents the results from a questionnaire sent out to users of the web version 
of the SFINX database. The questionnaire was designed to receive answers on when 
and how SFINX is used and also how it is perceived by the users. The questionnaire 
was sent out to all registered users (n=11 763).   
 
4.4.2 Results 
Answers from 1389 prescribers and 464 pharmacists were included in the study. The 
database was stated to be used weekly or more often by 45% of the prescribers and 
51% of the pharmacists. The prescribers reported using the database when meeting 
patients (60%) or directly before/after (60%). Pharmacists mostly used the database 
when dispensing drugs to patients (figure 3). Prescribers also reported using the 
database for drug utilization reviews and education.   
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Figure 3. In which situation do prescribers/pharmacists use the database? 
 
Changes in prescribing were reported to occur sometimes or more often by 74% of the 
prescribers. Among the most common changes, due to the use of SFINX, was changing 
the drug and informing the patient.  Among pharmacists, 93% reported changing their 
handling of the patient and the most common action was to contact the prescriber 
followed by informing the patient. Twenty percent of prescribers and twenty five 
percent of pharmacists reported that the information provided by SFINX was irrelevant 
sometimes or more often.  
 
 
4.5  STUDY V 
4.5.1 Design  
The number of potential drug-drug interactions before and after implementation of 
SFINX into and electronic health record system was investigated in a controlled study. 
Primary health care centers in the northwestern part of Stockholm were included in the 
study. Data from a 4 month period before implementation and for the same months the 
year of implementation were compared. A control group not using SFINX was also 
included in the study. Data was retrieved from the Swedish Prescribed Drug Register.  
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4.5.2 Results 
In total, twenty health care centers participated in the study, fifteen in the SFINX group 
and five in the control group. Data on approximately 91 000 prescriptions to 25 000 
patients was analyzed per period. We found a significant, 17% decrease in the number 
of potential drug interactions in the group using SFINX while the change in the control 
group was non-significant. Logistic regression did not show any significant difference 
between the two groups. The study did have very low power to show any difference 
since the control group was smaller than aimed for. 
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5 DISCUSSION 
Detecting and managing interactions between drugs is a clinical challenge. Drug-drug 
interaction warning systems play a major role in aiding physicians, other prescribers, 
and pharmacists when prescribing or dispensing drugs to patients. Despite the fact that 
warning systems are being introduced at most health care facilities, many patients are 
still prescribed potentially harmful drug combinations. The reasons behind this 
phenomenon are not known. However, possible explanations are incomplete patient 
drug lists in an electronic health record system, underuse due to bad integration of the 
system and over-alerting. In many cases, drug-drug interactions do not have any 
clinical consequences at all, and the combination may be well tolerated. In some cases, 
the specific combination may intentionally be prescribed to a specific patient for 
beneficial effect, despite being judged as a combination that usually should be avoided. 
One such example is co-prescription of verapamil and metoprolol, a combination that 
can cause atrioventricular block, bradycardia and hypotension [172]. In general, this 
interaction should be avoided, but it may in some cases be beneficial. Other interactions 
do have clinical impact and may cause serious adverse effects or result in therapeutic 
failure.  
 
The main scope of this thesis was to design a knowledge database, and to measure user 
satisfaction, and impact on prescribing when the database is used and integrated into an 
electronic health record system. When designing the database SFINX, we wanted to 
create a knowledge database useful in the clinical situation. Alerts should, as far as 
possible, aid drug prescribing without annoying the users or give unnecessary 
warnings.  The main tools to improve the signal to noise ratio were to classify drug 
interactions and to give warnings based on administration routes for the drugs. To make 
it easy to use when meeting patients, we aimed at writing short, stringent texts 
describing the clinical consequence of the interaction and to give clinically useful 
recommendations. Strategies used are described and discussed below.  
 
 
5.1 STRATEGIES FOR USEFUL DRUG-DRUG KNOWLEDGE BASES 
5.1.1 Classification of drug-drug interactions 
Classifying of drug-drug interactions according to clinical relevance has been shown to 
be an efficient way to increase acceptance of drug-drug interaction warnings [163;173]. 
The classification system from a previous Swedish drug-drug interaction warning 
system [20] was well accepted and known by the Swedish users. This classification 
system was only slightly modified to be able to show where interactions were 
extrapolated to similar drugs in the SFINX database. In SFINX, the interactions are 
graded from A to D according to clinical relevance and from 0 to 4 according to level 
of documentation.  
 
The grading of drug-drug interactions makes it possible to differentiate the type of 
warnings when SFINX is used in a CDSS. Our recommendation is to use different 
color coding for the different interactions where D should be red, C yellow and B and 
A white. Color coding may be one approach to inform the prescriber about the 
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existence of a certain type of interaction [164]. Another option would be to show all C- 
and D-interactions in an intrusive manner, whereas B and A could be shown in the 
prescribing system without any interruption.   
 
One problem with color coding may be that prescribers only recognizes the colored 
interactions and totally disregards the other interactions.  Some prescribers may even 
only react on red warnings, which might be dangerous, since many C interactions are as 
severe as D interactions if no action is taken. In study IV, 17% of the prescribers 
reported reading only the texts for C and D interactions, whereas 4% reported reading 
only the texts for D-interactions.  
 
 B-interactions are those where the ‘clinical outcome of the interaction is uncertain 
and/or may vary’. In this group there are interactions where exposures are somewhat 
altered in the whole population, but where the clinical consequence is unknown. We 
also have B-classified interactions that are based on one or a few case reports and 
where we have found no other evidence for the interaction. Some of the interactions 
that are B-classified occur only in some patients but not in others, maybe due to genetic 
factors such as e.g. the dependence of the CYP2C9*3 allele as found in study III.  In 
some cases, a B-interaction may be as severe as a D-interaction and hiding this 
information may result in unwanted unawareness. The optimal way, in my opinion, is 
to have the B-interactions in the system but shown in a non-alarming way. If the 
physician sees a patient describing side effects, this information can be read and maybe 
the interaction is the cause of adverse effects in this patient.  It is important to know that 
the database can be used not only for screening of interactions, but it is also a valuable 
tool to find a reason for an occurring drug problem.  
 
5.1.2 Inclusion criteria 
The number of interactions included in the knowledge base will influence the number 
of warnings given. If all possible interactions, both pharmacokinetic and 
pharmacodynamic are included, the number of interactions in the database will be very 
large. In SFINX, we have decided to mainly include pharmacokinetic interactions, but 
we are also including pharmacodynamic interactions that are not obvious due to the 
action of the drugs. For example, we do not warn for concomitant use of beta 
stimulants and beta blockers, since that interaction is expected if you know about how 
the drugs work. An example of a pharmacodynamic interaction that is included is the 
interaction between NSAIDs and SSRIs, causing an increased risk for hemorrhage. Not 
everybody knows that SSRIs increase the risk for bleeding and the risk is also more 
than additive, hence this interaction is included in SFINX. Of course, there are many 
prescribers and pharmacists that would like to be warned even about the obvious 
pharmacodynamic interactions, but we assume that by adding them the signal to noise 
ratio would be unfavorable, increasing the risk for alert fatigue.  
 
To make it possible for prescribers to evaluate the risk for some pharmacodynamic 
interactions we have developed Pharmacological Risk Assessment Online (Pharao) as a 
new tool. In Pharao we have graded all substances in SFINX according to their risk for 
causing anticholinergic side effects, hemorrhage, serotonin syndrome, QT 
prolongation, seizures, constipation, sedation, orthostatic hypotension and renal 
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toxicity. The substances are graded from 0 to 3 and we have made algorithms to 
calculate if the risk is mild, moderate or severe for each of the properties. A sum is 
calculated for each property, and the user receives a color coded warning according to 
the risk level. We do want Pharao to be an on-demand system, since mandatory use 
during prescribing would probably rapidly result in alert fatigue. 
 
5.1.3 Substances and dosage forms 
In the previous drug-drug interaction warning system used in Sweden, a lot of 
interactions were group interactions, according to ATC-codes. This caused some 
unintentional warnings, for example glucosamine was classified as a NSAID, although 
glucosamine does not have any similarities with NSAIDs. The same problem has been 
reported for other drug-drug interaction warning systems [165]. To prevent this, all 
interaction texts in SFINX are written at substance level, although there is a possibility 
to share texts between several interacting pairs. The sharing feature diminishes 
unintentional differences between texts. 
 
Some drug-drug interaction warning systems do warn incorrectly for drug interactions 
with topical drugs that are not absorbed [165]. Irrelevant warnings may also be given 
for drugs administered parenterally if the drug interacts only when given orally, as in 
the case of chelate formation. This makes the system less specific and causes erroneous 
warnings, annoying the users. A feature to reduce this type of errors was introduced in 
SFINX by taking route of administration into account when classifying interactions. 
Any of these routes can be added to an interaction: enteral, parenteral, enteral oral, 
enteral non-oral and topical, to increase the specificity for of the warnings. One 
example of a substance where the dosage form is important is midazolam, where the 
interaction with CYP3A4 inhibitors is much more pronounced if given orally compared 
to parenterally [174]. In SFINX the interaction between oral midazolam and protease 
inhibitors is D-classified whereas if given parenteral it is classified as C. These 
classification options prevent unnecessary warnings especially when drugs are 
administered topically.   
 
5.1.4 Recommendations 
Lack of management advice is common in drug-drug interaction warning systems and 
recommendations is a feature that users demand [165].  In a survey in the United States, 
74% of prescribers and 82% of pharmacists stated that they wanted management 
alternatives when given drug-drug interaction warnings [167]. To facilitate the handling 
of interactions, recommendations are given for all interactions in the SFINX database. 
Recommendations can be that the patient should be carefully monitored for adverse 
effects, that the drug concentration should be measured or another alternative drug can 
be used. The recommendations are aimed at being as specific as possible, but in many 
cases this is difficult since there are no better alternative drugs available, or drug 
concentrations are not possible to measure. Even indications of the drugs involved vary, 
and may alter the recommendation texts. The evidence behind the recommendations is 
varying, some are based on results from clinical trials while others are based on known 
pharmacological substance properties. Often, both actions to handle the interaction and 
alternative drugs are given. Unfortunately, we do not know to what extent SFINX users 
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adhere to the recommendations or if they find them useful enough. In study IV it would 
have been of value to add a question about the content and usefulness of the 
recommendations, but unfortunately we did not do this. Another way to study the 
adherence would be to follow up some specific recommendations within the patient 
medical journal e.g. if drug levels were measured, doses decreased or increased or if the 
given alternative drug was chosen. The most common answer, in study IV, on the 
question about what actions were taken due to information from SFINX was to change 
the choice of drug (74%). We do not know if they change to alternatives given in the 
recommendation texts or if they only change because there is a warning. This would 
require further investigations including follow-up on drug treatment after using drug-
drug interaction warning systems.  
 
5.1.5 Implementation 
Another important, but often neglected, step for optimizing drug-drug interaction 
warnings is the implementation of the knowledge base into electronic health record 
systems. The user interface is really important and it does not matter how consummate 
the database is if it is not presented in an optimal way to the users. It is also important 
that the users feel involved in the implementation for the process to succeed [175]. In 
study V, which yet is the only available study of effects of SFINX on prescription of 
interactions, SFINX was introduced in health care centers using Swedestar (an 
electronic health record system). The health care centers were contacted and asked 
about if they wanted education on the new features of the system, but only four out of 
fifteen centers had received this information. In the other health care centers the users 
had only received a pamphlet about the system. Also when SFINX was introduced into 
the electronic health care records system, Take Care, used at Karolinska university 
hospital, information about the system did not reach the prescribers sufficiently.  The 
system is non-intrusive and many users may not have noticed the warnings at all.  
 
Unfortunately, the providers of knowledge bases are, most of the times, not involved 
when the system is integrated into the electronic health records. This may result in 
inappropriate displaying of warnings, underuse and even false integrations. 
 
Also, when integrating the CDSSs it is of importance to find out when in the 
prescribing process the prescribers wants the warnings. If the warning is given to late or 
has a bad timing the physician will have difficulties in using the given warning [176].   
 
5.1.6 Preventing alert fatigue and overriding 
Since alert fatigue and overriding is common for drug-drug interaction warnings, it is 
important to try to minimize these problems. All the above mentioned strategies are 
attempts to reduce irrelevant alerts and increase alert acceptance. Several studies have 
shown that drug alerts are often overridden due to reasons such as that the user finds the 
warnings unnecessary, the medication list is not up-dated causing excessive warnings 
and warnings are shown repeatedly [177;178].  
 
There are yet not studies investigating the override rates for the warnings given by 
SFINX. In study IV, one of the questions was how often the respondents find the 
information irrelevant. On that question 20% of prescribers and 25% of pharmacists 
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answered sometimes or more often. Since this questionnaire was answered by users of 
the web version, the figure can be expected to be a bit higher if studying this among 
users of SFINX integrated into the prescribing systems. 
 
5.1.7 Evaluation  
Every knowledge base should be evaluated for quality assurance and further 
development. Evaluation can be done in several ways. By studying logging of usage 
one can look at how it is use, what texts are read etc. That is valuable information about 
the usage. Other ways are to do more qualitative research including questionnaires and 
interviews. Effects of use of knowledge bases on prescriptions and patient outcome are 
also important to study and discussed in 5.2.2 below.  
 
In study IV we attempted to evaluate how the web version of SFINX is used and how 
the users perceive the application and the information provided. No other formal 
studies issuing this question have been performed yet, despite SFINX being widely 
used in Sweden and Finland. The answers on the questionnaire gave us much 
information about how and when the database is used. We learned more about how the 
users perceive the database. In the questionnaire many users stated that they wanted 
information about herb-drug interactions and some were later introduced into SFINX. 
Unfortunately, this feature cannot be sufficiently used in the integrated versions since 
herbal drugs are usually not prescribed through electronic health record systems. 
However, in the web version one can easily search for herb-drug interactions.  
 
 
5.2 EPIDEMIOLOGY OF DRUG-DRUG INTERACTIONS 
5.2.1 Measuring drug-drug interactions 
There are difficulties in measuring the exposure to possible drug-drug interactions.  In 
study V, we have used all dispensed drugs during a four-month period to estimate the 
exposure to drugs and their interactions. In Sweden, drugs are usually dispensed for a 
three-month period. It has been shown that by looking at dispensed drugs during a four-
month period you are more likely to cover drugs used for chronic disorders [179], since 
some patients take out their drug when only a few tablets are left in the package, which 
might often be more than 90 days after the first purchase. However, by classifying all 
drugs dispensed to a patient during a four-month period, it is likely that we will slightly 
overestimate the number of drug interactions. By using the Swedish Prescribed Drug 
Register, we can only identify drugs that the patient has been prescribed and purchased 
at the pharmacy. In our opinion, this method gives a more correct measurement of drug 
use in the patient compared to looking at prescription data in the electronic health 
records. Depending on what you want to measure you should choose the most 
appropriate method. If you want to measure how many interacting drugs the physicians 
actually prescribe it would be better to look at prescriptions, but if we want to look at a 
more true exposure it is better to use the Prescribed Drug Register. Another reason for 
using the Prescribed Drug Register is that data on all drugs dispensed is available 
whereas data on prescriptions is today not as easily available for research. 
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In our study, we do not have any information about drugs that patients might have 
purchased over the counter. Additionally, we do not know if the physicians have done 
anything to prevent the interactions. For many of the interactions found, one of the 
easiest ways to avoid them is to take a temporary brake with one of the interacting 
drugs (such as iron or calcium) or to take them several hours apart. Such an action 
cannot be identified using register data, especially when drug dosing regimens cannot 
be interpreted. Also, we probably overestimate the prevalence of interactions since 
some of the interacting pairs have not at all been taken at the same time during the four 
months period. For example, a patient may have used erythromycin for one week in the 
beginning of the four month period and then was prescribed a calcium channel blocker 
several weeks later. By using our method, this will still be classified as an interaction. 
 
The number of patients exposed to potentially serious drug-drug interactions in study V 
was lower (1.5%) than previously reported (2.9%) in Sweden [180]. Our study is only 
based on data on all prescriptions from one health care center and does not include the 
drugs that the patients have been prescribed elsewhere. We have also excluded patients 
using multiple drug dose dispensing. It has been shown that patients using multiple 
drug dose dispensing are more likely to be exposed to drug interactions [181].  
 
5.2.2 Studying clinical effects of drug-drug interaction warnings 
It is generally assumed that the prevalence of drug-drug interactions will decrease if 
warnings are given to prescribers. Many studies have investigated the effect but with 
diverging results. The prevalence of interactions is assumed to be a proxy for the 
prevalence of clinically consequences due to drug-drug interactions. There are not 
enough studies published yet to show if warnings actually decreases hospitalizations 
etc. [160]. 
 
In study V, we looked at the influence of integration of SFINX on the prevalence of 
potentially serious drug-drug interactions and we found a significant 17% decrease. 
One can speculate if a 17% decrease does have any clinical consequences at all. For 
many of the D interactions we cannot know if the patient has been exposed or not since 
it cannot be observed by looking at dispensing data. Examples are all the chelate 
formation interactions where the prescribers may have informed the patient about how 
to avoid the interaction. Taking that into account the number of prevented drug-drug 
interactions could be much higher, but we do not have any information about that.  
 
Today, when much health care money is spent on clinical decision support systems, 
there is an urgent need for studies on the clinical impact of these systems. 
Unfortunately, they are not easily performed and not even asked for by the counties 
paying for the decision support systems. When doing this kind of studies the benefits 
should be weighed against the time use of the system consumes. 
 
5.2.3 Common drug-drug interactions 
In study V, we found that the most common potentially serious drug-drug interactions 
were those resulting in chelate formation between antibiotics and metal ions or calcium. 
We do not know if the prescribers have taken any action to prevent these interactions, 
e.g. advised the patient to separate drug intake by several hours or skipping the 
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metal/calcium therapy during antibiotic treatment.  Co-prescription of potassium and 
potassium sparing diuretics was also common. In this case co-treatment may be 
justified if the potassium levels are monitored closely but otherwise the interaction 
should be avoided. Another common group of interactions are those between opiates 
that need to be metabolized by CYP2D6 to become active (codeine, tramadol, 
ethylmorphine) and inhibitors of CYP2D6 (fluoxetine, paroxetine, duloxetine, 
terbinafine, bupropion). These interactions causes lack of effect and may be less easy to 
identify than serious interactions that causes side effects. Among the common 
interactions in study V, were also interactions between calcium channel blockers 
(felodipine, nifedipine) and enzyme inducers (carbamazepine, phenytoin). These 
interactions will also cause loss of the blood pressure lowering effect of the calcium 
channel blockers.  
 
Actions to avoid drug interactions resulting in decreased effect seem to be less than for 
interactions resulting in adverse effects. It has been shown that physicians are more 
likely to prescribe CYP2D6 inhibitors together with prodrugs such as codeine and 
tamoxifen than prescribing CYP2D6 inhibitors and substrates [182]. Such interactions 
could probably be reduced by using a warning system. Increased knowledge about 
them could also increase the awareness about them. Many of those interactions did 
decrease in study V and maybe the prescribers learned about this kind of interactions 
from the database.  
 
5.3 SFINX – HAVE WE REACHED OUR GOAL? 
We aimed to create a knowledge base of drug-drug interactions that should be suitable 
for integration into electronic health records, clinically useful and not causing 
unnecessary warnings.  
 
First of all we have created a knowledge base, SFINX, and it is integrated into 
electronic health care records in Sweden, Finland and Italy.  Today, the knowledge base 
contains over 17 000 drug-drug interaction warnings and it is updated quarterly.  
Based on the results from study IV, we can conclude that SFINX is used when 
prescribers and pharmacists meet their patients. Users report that the information does 
have impact on their prescribing/dispensing.  Of course, the respondents are a selected 
group of SFINX users and we do not know how the system is used and perceived 
among users of the electronic health record integrated version of SFINX.  
 
The results from study IV can be seen as an indication that we have reached our goal, 
although more information both of the clinical usefulness and the frequency of 
unnecessary warnings is needed to confirm this. A further goal that could be set is that 
SFINX should decrease adverse outcomes due to drug-drug interactions. It is our hope 
that it does but this would need to be confirmed in a large randomized controlled trial. 
 
 
5.4 FURTHER REDUCTION OF IRRELEVANT WARNINGS 
As shown in study III, some drug-drug interactions may only occur in genetically 
predisposed patients. Many of these interactions may in SFINX be classified as B-
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interactions since they are not that common and may only occur in some patients. One 
way to further improve drug-drug interaction warning systems could be to warn 
specifically if a patient has, for example, a genotype predisposing them for a given 
interaction.  For such a system to work we need to have much more knowledge in the 
area, otherwise it would be difficult to give clear recommendations on how to handle 
the interactions within these relatively uncommon patient groups. Also, the electronic 
health record system would need to store the information, e.g. genotype needed to 
specify the alert. One should also bear in mind that for many drugs there are wide 
spread differences in exposure that cannot be explained by any, yet known, genetic 
factor. In our warfarin dosage model in study III we could only explain around 62% of 
the variation in warfarin dosage when including age, gender, use of simvastatin and 
mutations in CYP2C9 in the analysis. Other factors that could be included to produce 
more specific warnings are e.g. kidney function and liver function.  
 
Another way, not used today, would be to adjust warnings according to the patients 
prescribed dose. Such a limit could be set for example for statins where it has been 
shown that some interactions are probably irrelevant if statins are given in low doses 
[183].  
 
5.5 SOURCES FOR STUDIES OF DRUG-DRUG INTERACTIONS 
Today the regulatory authorities demand drug interaction studies to be performed 
before a new drug is approved. This gives information about the general drug 
interaction properties of these drugs. For older drugs much information is missing and 
drug companies do not have any economic interest in performing these studies. To find 
indications of interactions the optimal way is to use already collected data. In study II, 
we used the therapeutic drug monitoring database to investigate the interaction between 
lamotrigine and quetiapine. Data from therapeutic drug monitoring is useful for 
performing drug interaction studies and the drugs analyzed are often those with a 
narrow therapeutic interval where drug-drug interactions may be more likely to have 
clinical impact. Another way to identify, still unknown, interactions is using data 
mining in pharmacovigilance databases [184]. It has also been shown that drug 
interactions can be found based on data mining from searches in Google, Bing and 
Yahoo! [185]. In a study, not included in this thesis, we have also shown that drug 
interactions with warfarin actually can be identified by analyzing dispensing data from 
the Swedish Prescribed Drug Register [186]. Analyzing of data on diagnoses and drugs 
used could also be extracted from electronic health records and used for analysis of 
drug-drug interactions. Linking data from in-patient register with data on prescription is 
another option to find drug interactions. Table 3 gives a short summary of examples of 
sources to find drug-drug interactions.  
 
Findings based on above mentioned database investigations should always only be 
considered as indications of a drug-drug interaction and not as a proof. But they might 
be helpful to find which drug-drug interaction studies that should performed.  
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Source Examples 
Pharmacovigilance databases Swedis 
EMA database 
Vigibase 
Routine data from health care TDM databases 
Electronic health records 
Search engine data  Google etc.  
Health registers Prescribed Drug Register 
In-patient Register 
Health care quality registers 
Table 3. Example of sources to indentify new drug-drug interactions. 
 
5.6 INTERACTIONS INVOLVING GLUCURONIDATION OF QUETIAPINE 
In study II, we show that co-treatment with lamotrigine decreases the concentration of 
quetiapine. The findings in this study should be used with caution since we only had 
data from 22 exposed patients. The effect is, however, larger than that previously 
reported by Castberg et al [187] and could have clinical impact. The combination of 
lamotrigine and quetiapine is commonly used among patients suffering from bipolar 
disorder. When they are used together they could theoretically have a synergistic effect 
making them work well enough despite the lowered concentration of quetiapine. The 
situation could be another in a patient using lamotrigine for epilepsy and quetiapine for 
treatment of schizophrenia. In that case addition of lamotrigine to ongoing quetiapine 
treatment could possibly result in worsening of the psychiatric disease.  
 
The results from this study supports the theory that glucuronidation may be important 
for the elimination of quetiapine, and that drugs inducing or inhibiting glucuronidation 
may influence the pharmacokinetics of quetiapine. Since most inducers of UGTs are 
also inducers of CYP3A4 it is difficult to find out which induction that is causing 
changes in the pharmacokinetics but this could probably be done by analyzing all 
metabolites. Sparse data describe an increased concentration of quetiapine in patients 
using valproic acid [188] and this also supports the evidence of glucuronidation as an 
important pathway for quetiapine metabolism. 
 
Of interest is also the inducing effect of lamotrigine, which may result in other 
important drug interactions. For example, somewhat lowered levonorgestrel 
concentration has been reported in patients treated with lamotrigine [189], and this 
could possibly be due to increased glucuronidation. Decreased clonazepam 
concentration has also been reported [190], strengthening the assumption that 
lamotrigine is an inducer of at least some UGTs.  
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5.7 INHIBITION OF CYP2C9*3 BY SIMVASTATIN 
In study III we show that the interaction between simvastatin and warfarin is more 
pronounced in patients with the CYP2C9*3 allele. The results from the multiple 
regression analysis indicate that the interaction may even be present only in patients 
carrying the *3 allele. We speculate that this may be due to selective inhibition, either 
by simvastatin acid or simvastatin lactone, of the CYP2C9*3 enzyme, but this still 
needs to be proven. It is already known that the pharmacokinetics of different CYP2C9 
substrates is altered differently by polymorphisms in the gene encoding for CYP2C9. 
The clearance of S-warfarin is reduced by 48% in patients with the CYP2C9*1/*3 
genotype, whereas the clearance of diclofenac is not significantly altered [191]. It has 
also been speculated that fluconazole, a potent CYP2C9 inhibitor, may not at all inhibit 
CYP2C9*3 [192].  
 
Due to a response letter to our publication [193], we reanalyzed data from study III. In 
the new analysis we included information about mutations in the VKORC1 gene 
encoding for warfarin’s target molecule. In this analysis there was still a significant 
effect of simvastatin use in patients with the CYP2C9*3 allele. 
 
Selective inhibition of CYPs due to genetic polymorphisms is poorly investigated. For 
warfarin there are many single case reports of pronounced interactions whereas no 
interaction can be observed in clinical trials. These interactions could, theoretically, in 
some cases be due to selective inhibition of certain variants of the CYP2C9 enzyme. 
 
5.8 OPTIMIZING DRUG-DRUG INTERACTION WARNINGS 
The optimal drug-drug interaction warning system should be flexible and easily 
individualized. All warnings should be accessible, although only those that are deemed 
clinically relevant should be shown. The warnings should be shown at the optimal time 
when prescribing e.g. as soon as the physician has chosen the drug and decided the 
dose. The user should be able to adjust the level of warnings shown and it should be 
possible to switch off warnings. The possibility to switch off warnings should be 
available both for a specific user but it should also be possible avoid certain warnings 
for a specific patient. Ideally, the system should also be able to customize warnings 
depending on more sophisticated patient characteristics.  For example interactions 
occurring only in persons with certain genotypes should only be shown in patients not 
genotyped or known to have the predisposing genotype. The system could as well be 
linked to laboratory parameters and e.g. warn when patient using potassium and 
potassium sparing diuretics have high potassium levels or when potassium has not been 
measured within a certain time. This approach has already been tested. In a study from 
1994 warnings for interactions were generated if laboratory values were not measured 
within a few days after concomitant therapy had been initiated or if measurements 
taken were above certain limits. For example, in patients using digoxin and quinidine 
the digoxin concentration should be measured within 5 days and it should then be 
below a certain value not to generate any warning [194].  
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In cases where measuring of drug concentration is advisable it could have benefit if the 
user could easily order the concentration measurement when prescribing the potential 
interacting drugs. Warnings should also ideally be shown when one drug is withdrawn 
and if that drug is an inducer the warning should also inform the user that it can take 
some weeks until a new steady-state is reached.  Table 4 shows some factors that could 
possibly be useful for targeting drug-drug interaction alerts.  
 
Factor Explanation 
Age Some adverse effects are more common in 
elderly 
Renal function Decreased renal function may increase the risk 
for adverse effects 
Genotype for CYP, UGT, 
transporters etc. 
Some interactions may occur only in some 
patients
Dose Some interactions do not occur with low doses.  
Gender QT-prolongation is more common in women 
Plasma levels of drugs Warnings could be diminished if it is known that 
the patients concentration is within the 
therapeutic interval 
Other measurements such as 
serum potassium 
Warnings should be given only when potassium 
is not measured or high. 
Table 4. Examples of factors registered in the health care records that in the future 
could be used to decrease over-alerting. 
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6 FUTURE PERSPECTIVES 
Drug-drug interactions will continue to be a problem for drug prescribers and 
dispensing pharmacists. The prevalence of drug-drug interactions will probably 
increase, due to increasing polypharmacy, and more sophisticated methods for 
identifying and handling drug-drug interactions will have to be developed. Today many 
physicians are not aware of what drugs a patient is using, making it almost impossible 
for them to know of potential drug-drug interactions. In an ongoing study we attempt to 
quantify this problem using data on prescriptions patients have received both from their 
primary health care centers and from other prescribers.  In Sweden there is an ongoing 
project to develop a national database of medication orders. The aim of this database is 
to store all the patients’ medication orders and make the list reachable from all 
electronic health care systems used in the country.  It is advisable to link a clinical 
decision support systems (including SFINX) to this complete drug list to support the 
users [195]. 
 
In this thesis we have evaluated the impact of SFINX on prescribing and analyzed user 
perception. The findings are interesting but there is much more that could be done to 
gain additional knowledge. The study investigating the impact of SFINX on prescribing 
of potentially serious drug-drug interactions could be done in a different setting with 
larger study groups. SFINX should then ideally be implemented in another manner and 
all users should be taught how to use the system. Another, even more interesting study, 
would be to actually track what actions users have taken according to the information in 
SFINX. This could be done either automatically logging all searches in the database or 
also logging all drugs prescribed. Another way would be to invite physicians to 
participate in a study where they are asked to give information about how they have 
specifically handled the certain interaction warnings they have received.  
 
Regarding how the users perceive SFINX one should ideally perform another 
questionnaire study for users of SFINX integrated into the electronic health records. 
The questionnaire should have a focus on alert fatigue and overriding since this is the 
major problem with drug-drug interaction warning system. Interviews with users could 
also give more information on how SFINX is perceived.  
 
The SFINX database could probably be improved by addition of more herbal drugs. 
Another feature that could be added to improve usefulness would be to add drug 
combinations with evidence for lack of interaction. This should of course be an on-
demand feature and not something that the prescriber is forced to see. To avoid over-
alerting other algorithms such as drug dosage or further patient specific data (kidney 
and/or liver function, certain genotypes) could be integrated into the system. 
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The interaction between lamotrigine and quetiapine should ideally be investigated in a 
cross-over study either in patients or in volunteers. The dependence of CYP2C9*3 on 
the interaction between simvastatin and warfarin should, if possible, be confirmed (or 
discarded) in a larger patient material. It would also be possible to make a clinical trial 
comparing patients with CYP2C9*1/*1 genotype to patients with CYP2C9*1/*3 
genotype. The results from an in vitro study investigating if simvastatin is a selective 
inhibitor of CYP2C9*3 would be informative.  
 38 
 
7 ACKNOWLEDGEMENTS 
I would like to thank all who have made this thesis possible and who have enlightened 
my life during my time as a PhD student. I would especially like to thank:  
 
Ylva Böttiger, my main supervisor, for letting me do things my own way. Also, thank 
you for always being wise and a real pro in constructive problem solving.  
 
Jonatan Lindh, my co-supervisor, for enthusiastic discussions about statistics, for 
joining me in learning R, answering e-mails around the clock, and for drink evenings.  
 
Birgit Eiermann, my co-supervisor, for sharing you knowledge about clinical decision 
support systems, and your mental support when problems have occurred during my 
time as a PhD student. 
 
All my co-authors, for fruitful cooperation. Special thanks to Linda Björkhem- 
Bergman for your enthusiasm, without you paper II would never have been written. 
Also thanks to Marie-Louise Ovesjö for nice breakfast company and valuable input on 
manuscripts.  
 
Every, both past and present, member of the SFINX group (especially Margaretha 
Julander, Kari Laine, Tuomas Korhonen, Tero Shemmeika, Emma Hultén and 
Tuire Prami). I enjoy working with you.  
 
Annika Asplund, my colleague for more than 10 years, thanks for your kindness and 
friendship. Thank you also for last minute proof reading of the manuscript.  
 
Annica Bergendal, for making klin farm an even more fun place.  
 
Lars L Gustafsson, for encouragement and interesting discussions. 
 
Fadiea Al-Aieshy and Rana Said, for fun times. I really wish that we can go tenting 
together sometime in the future.  
 
Mariann Sondell, for enthusiastic sharing of flower knowledge.  
 
Sofia Nordenmalm, for being an excellent substitute while I have been doing science 
and been on parental leave. I am glad you are staying at the department.  
 
Catarina Cleveson, for excellent assistance before the dissertation.   
 
Folke Sjöqvist, for development of the first Swedish drug-drug interaction source and 
for establishin the discipline of clinical pharmacology in Sweden.  
 
All co-workers, past and present, at the department of clinical pharmacology. It is 
always fun to go to work thanks to you.   
 39 
 
My parents, Ingela and Jerry Andersson, for making me interested in nature and 
nature sciences.   
 
My brother, Rickard Andersson, for being my role model from infancy to adulthood. 
 
Gry, my daughter, for being a constant beam of sunlight.  
 
Stefan Jansson, for your love, support, and endless patience.  
 
 40 
 
8 REFERENCES 
 
1  Rang.H.P, Dale.M., Ritter.J.M. Pharmacology. 4th ed. Edinburgh: Churchill 
Livingstone; 1999. 
 2 Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 
1963;2(7313):849-850. 
 3 Miller RB. Tranylcypromine and cheese. Br Med J 1963;2(5372):1593. 
 4 Natoff IL. Cheese and monoamine oxidase inhibitors. Interaction in anaesthetized 
cats. Lancet 1964;1(7332):532-533. 
 5 Phenylbutazone. ChemIDplus Lite, cited 2014 Mar. 10; Available from: 
URL:http://chem2.sis.nlm.nih.gov/chemidplus/chemidlite.jsp 
 6 Gulbrandsen R. Økt tolbutamideffekt ved hjelp av fenylbutazon?. Tidsskr Nor 
Laegeforen 1959;79:1127-1128. 
 7 Pestalozzi H, Clauss A, Sigg A. Retardwirkung von Butazolidin auf die 
Antikoagulantien vom Dicumaroltyp. Helv Med Acta 1956;23(4-5):589-591. 
 8 Lewis RJ, Trager WF, Chan KK, Breckenridge A, Orme M, Roland M et al. 
Warfarin. Stereochemical aspects of its metabolism and the interaction with 
phenylbutazone. J Clin Invest 1974;53(6):1607-1617. 
 9 Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. 
Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver 
cytochrome P4502C9. Biochem Biophys Res Commun 1991;175(3):1112-1118. 
 10 Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G. 
Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of 
phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 2004;60(3):173-
182. 
 11 Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T et al. 
Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role 
for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 
1992;5(1):54-59. 
 12 Christensen LK, Hansen JM, Kristensen M. Sulphaphenazole-induced 
hypoglycaemic attacks in tolbutamide-treated diabetics. Lancet 
1963;2(7321):1298-1301. 
 13 Burns JJ, Conney AH. Enzyme stimulation and inhibition in the metabolism of 
drugs. Proc R Soc Med 1965;58(11 Part 2):955-960. 
 14 Fouts JR. Drug interactions: effects of drugs and chemicals on drug metabolism. 
Gastroenterology 1964;46:486-490. 
 15 Vesell ES, Page JG. Genetic control of dicumarol levels in man. J Clin Invest 
1968;47(12):2657-2663. 
 41 
 
 16 Vesell ES, Page JG. Genetic control of drug levels in man: phenylbutazone. 
Science 1968;159(3822):1479-1480. 
 17 Alexanderson B, Evans DA, Sjöqvist F. Steady-state plasma levels of 
nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 
1969;4(5686):764-768. 
 18 Conney AH. Induction of drug-metabolizing enzymes: a path to the discovery of 
multiple cytochromes P450. Annu Rev Pharmacol Toxicol 2003;43:1-30. 
 19 FASS 1970. Stockholm: Läkemedelsinformation AB; 1970. 
 20 Sjöqvist F. A new classification system for drug interactions. Eur J Clin 
Pharmacol 1997;52(Suppl):377a. 
 21 Eliasson M, Bastholm P, Forsberg P, Henriksson K, Jacobson L, Nilsson A et al. 
Janus computerised prescribing system provides pharmacological knowledge at 
point of care - design, development and proof of concept. Eur J Clin Pharmacol 
2006;62(4):251-258. 
 22 FDA. Guidance for industry, Drug interaction studies - Study design, data 
analysis, implications for dosing, and labeling recommendations. Draft Guidance.  
2012.  
 23 EMA. Guideline on the investigation of drug interactions.  2012.  
 24 Bergk V, Haefeli WE, Gasse C, Brenner H, Martin-Facklam M. Information 
deficits in the summary of product characteristics preclude an optimal 
management of drug interactions: a comparison with evidence from the literature. 
Eur J Clin Pharmacol 2005;61(5-6):327-335. 
 25 Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug 
Deliv Rev 1999;36(2-3):179-194. 
 26 de L, I, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the 
transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 
1992;189(1):551-557. 
 27 Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein 
transports cyclosporin A and FK506. J Biol Chem 1993;268(9):6077-6080. 
 28 Gosland MP, Lum BL, Sikic BI. Reversal by cefoperazone of resistance to 
etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma 
cells. Cancer Res 1989;49(24 Pt 1):6901-6905. 
 29 Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 
1B1: a genetically polymorphic transporter of major importance for hepatic drug 
uptake. Pharmacol Rev 2011;63(1):157-181. 
 30 Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism 
markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet 
Genomics 2006;16(12):873-879. 
 42 
 
 31 Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. Polymorphism in human 
organic cation transporters and metformin action. Pharmacogenomics 
2008;9(4):415-422. 
 32 Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U et al. 
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine 
test. Br J Clin Pharmacol 1994;38(5):471-473. 
 33 Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-
450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the 
hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. 
Proc Natl Acad Sci U S A 1989;86(20):7696-7700. 
 34 Berthou F, Flinois JP, Ratanasavanh D, Beaune P, Riche C, Guillouzo A. 
Evidence for the involvement of several cytochromes P-450 in the first steps of 
caffeine metabolism by human liver microsomes. Drug Metab Dispos 
1991;19(3):561-567. 
 35 Zhang ZY, Kaminsky LS. Characterization of human cytochromes P450 involved 
in theophylline 8-hydroxylation. Biochem Pharmacol 1995;50(2):205-211. 
 36 McManus ME, Burgess WM, Veronese ME, Huggett A, Quattrochi LC, Tukey 
RH. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of 
food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer 
Res 1990;50(11):3367-3376. 
 37 Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 
in chemical carcinogenesis: implications for human variability in expression and 
enzyme activity. Pharmacogenetics 1995;5(5):259-274. 
 38 Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and 
carbamazepine induction of the metabolism of clozapine: evidence from a 
therapeutic drug monitoring service. Ther Drug Monit 1994;16(4):368-374. 
 39 Gillum JG, Sesler JM, Bruzzese VL, Israel DS, Polk RE. Induction of 
theophylline clearance by rifampin and rifabutin in healthy male volunteers. 
Antimicrob Agents Chemother 1996;40(8):1866-1869. 
 40 Fuhr U, Wolff T, Harder S, Schymanski P, Staib AH. Quinolone inhibition of 
cytochrome P-450-dependent caffeine metabolism in human liver microsomes. 
Drug Metab Dispos 1990;18(6):1005-1010. 
 41 Leemann T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): a major 
monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci 
1993;52(1):29-34. 
 42 Zilly W, Breimer DD, Richter E. Induction of drug metabolism in man after 
rifampicin treatment measured by increased hexobarbital and tolbutamide 
clearance. Eur J Clin Pharmacol 1975;9(2-3):219-227. 
 43 Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ et al. 
Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 
1991;49(4):420-425. 
 43 
 
 44 Transon C, Leemann T, Vogt N, Dayer P. In vivo inhibition profile of 
cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 
1995;58(4):412-417. 
 45 Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and 
sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. 
Drug Metab Dispos 2002;30(6):631-635. 
 46 Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R et al. 
Interphenotype differences in disposition and effect on gastrin levels of 
omeprazole--suitability of omeprazole as a probe for CYP2C19. Br J Clin 
Pharmacol 1995;39(5):511-518. 
 47 Jung F, Richardson TH, Raucy JL, Johnson EF. Diazepam metabolism by cDNA-
expressed human 2C P450s: identification of P4502C18 and P4502C19 as low 
K(M) diazepam N-demethylases. Drug Metab Dispos 1997;25(2):133-139. 
 48 von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader 
RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes 
mediating biotransformation, inhibitory effects, and comparison to R-citalopram. 
Drug Metab Dispos 2001;29(8):1102-1109. 
 49 Feng HJ, Huang SL, Wang W, Zhou HH. The induction effect of rifampicin on 
activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and 
gene dose. Br J Clin Pharmacol 1998;45(1):27-29. 
 50 Wang LS, Zhou G, Zhu B, Wu J, Wang JG, bd El-Aty AM et al. St John's wort 
induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent 
hydroxylation of omeprazole. Clin Pharmacol Ther 2004;75(3):191-197. 
 51 Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of 
omeprazole treatment on diazepam plasma levels in slow versus normal rapid 
metabolizers of omeprazole. Clin Pharmacol Ther 1990;47(1):79-85. 
 52 Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose-
dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, 
fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51(1):73-78. 
 53 Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug 
codeine in human liver is mediated by the polymorphic monooxygenase 
catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem 
Biophys Res Commun 1988;152(1):411-416. 
 54 Young D, Midha KK, Fossler MJ, Hawes EM, Hubbard JW, McKay G et al. 
Effect of quinidine on the interconversion kinetics between haloperidol and 
reduced haloperidol in humans: implications for the involvement of cytochrome 
P450IID6. Eur J Clin Pharmacol 1993;44(5):433-438. 
 55 Lennard MS, Silas JH, Freestone S, Trevethick J. Defective metabolism of 
metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol 
1982;14(2):301-303. 
 44 
 
 56 Högstedt S, Lindberg B, Rane A. Increased oral clearance of metoprolol in 
pregnancy. Eur J Clin Pharmacol 1983;24(2):217-220. 
 57 Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of 
cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53(4):401-409. 
 58 von BC, Spina E, Birgersson C, Ericsson O, Göransson M, Henthorn T et al. 
Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver 
microsomes. Biochem Pharmacol 1985;34(14):2501-2505. 
 59 Leemann T, Dayer P, Meyer UA. Single-dose quinidine treatment inhibits 
metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 
1986;29(6):739-741. 
 60 Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive 
metabolizer to the poor metabolizer phenotype during treatment With bupropion. 
Ther Drug Monit 2002;24(3):436-437. 
 61 Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA et al. 
Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 
2005;25(3):226-229. 
 62 Brunton LL LJPK. Goodman & Gilman´s The pharmacological basis of 
therapeutics. 11 ed. New York: McGraw-Hill; 2006. 
 63 Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS et al. 
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo 
correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271(1):549-
556. 
 64 Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very 
susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin 
Pharmacol Ther 1998;63(3):332-341. 
 65 Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of 
cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine 
pharmacokinetics. Br J Clin Pharmacol 2006;61(1):58-69. 
 66 Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ. In vitro 
biotransformation of sildenafil (Viagra): identification of human cytochromes and 
potential drug interactions. Drug Metab Dispos 2000;28(4):392-397. 
 67 Bertilsson L, Tybring G, Widen J, Chang M, Tomson T. Carbamazepine 
treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has 
no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol 
1997;44(2):186-189. 
 68 Kocarek TA, Schuetz EG, Strom SC, Fisher RA, Guzelian PS. Comparative 
analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and 
human hepatocytes. Drug Metab Dispos 1995;23(3):415-421. 
 45 
 
 69 Fleishaker JC, Pearson LK, Peters GR. Phenytoin causes a rapid increase in 6 
beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A 
induction. J Pharm Sci 1995;84(3):292-294. 
 70 Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma 
concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59(1):7-
13. 
 71 Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St John's Wort: 
effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67(5):451-457. 
 72 Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH et al. 
Hepatic but not intestinal CYP3A4 displays dose-dependent induction by 
efavirenz in humans. Clin Pharmacol Ther 2002;72(1):1-9. 
 73 Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 
isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin 
Pharmacol 1997;44(2):190-194. 
 74 Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to 
patients receiving systemic antimycotics ketoconazole or itraconazole. Clin 
Pharmacol Ther 1994;56(6 Pt 1):601-607. 
 75 Pichard L, Fabre I, Fabre G, Domergue J, Saint AB, Mourad G et al. Cyclosporin 
A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 
(cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver 
microsomes. Drug Metab Dispos 1990;18(5):595-606. 
 76 Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human 
liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug 
Metab Dispos 1994;22(6):849-857. 
 77 Abbott FV, Palmour RM. Morphine-6-glucuronide: analgesic effects and receptor 
binding profile in rats. Life Sci 1988;43(21):1685-1695. 
 78 van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-
Beneken Kolmer EW, Caliskan-Yassen N et al. Lopinavir/ritonavir reduces 
lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 
2006;80(2):159-168. 
 79 Ebert U, Thong NQ, Oertel R, Kirch W. Effects of rifampicin and cimetidine on 
pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur 
J Clin Pharmacol 2000;56(4):299-304. 
 80 Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their 
role in drug metabolism and detoxification. Int J Biochem Cell Biol 
2013;45(6):1121-1132. 
 81 Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T et al. 
Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated 
protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 
predicts the disposition and modulates the effects of the cholesterol absorption 
inhibitor ezetimibe in humans. Clin Pharmacol Ther 2006;79(3):206-217. 
 46 
 
 82 Watanabe Y, Nakajima M, Ohashi N, Kume T, Yokoi T. Glucuronidation of 
etoposide in human liver microsomes is specifically catalyzed by UDP-
glucuronosyltransferase 1A1. Drug Metab Dispos 2003;31(5):589-595. 
 83 Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR et al. Genetic 
predisposition to the metabolism of irinotecan (CPT-11). Role of uridine 
diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its 
active metabolite (SN-38) in human liver microsomes. J Clin Invest 
1998;101(4):847-854. 
 84 Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 
genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann 
Oncol 1998;9(8):845-847. 
 85 Walle UK, Walle T. Induction of human UDP-glucuronosyltransferase UGT1A1 
by flavonoids-structural requirements. Drug Metab Dispos 2002;30(5):564-569. 
 86 Yaffe SJ, Levy G, Matsuzawa T, Baliah T. Enhancement of glucuronide-
conjugating capacity in a hyperbilirubinemic infant due to apparent enzyme 
induction by phenobarbital. N Engl J Med 1966;275(26):1461-1466. 
 87 Lee LS, Pham P, Flexner C. Unexpected drug-drug interactions in human 
immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux 
transporters by Efavirenz. Ann Acad Med Singapore 2012;41(12):559-562. 
 88 Gan J, Chen W, Shen H, Gao L, Hong Y, Tian Y et al. Repaglinide-gemfibrozil 
drug interaction: inhibition of repaglinide glucuronidation as a potential 
additional contributing mechanism. Br J Clin Pharmacol 2010;70(6):870-880. 
 89 Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro 
inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease 
inhibitors and the relationship of this property to in vivo bilirubin 
glucuronidation. Drug Metab Dispos 2005;33(11):1729-1739. 
 90 Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, Chiyoda T et al. 
Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral 
microdose and therapeutic dose. Pharmacogenet Genomics 2011;21(8):495-505. 
 91 Argikar UA, Remmel RP. Variation in glucuronidation of lamotrigine in human 
liver microsomes. Xenobiotica 2009;39(5):355-363. 
 92 Medication & herbal substrates, inhibitors & inducers of UGT enzymes drug 
table. Pharmacology Weekly 2014 , cited 2014 Mar. 23 
 93 Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-
glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol 
2002;17(5):233-238. 
 94 Ji HY, Lee H, Lim SR, Kim JH, Lee HS. Effect of efavirenz on UDP-
glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver 
microsomes. Molecules 2012;17(1):851-860. 
 47 
 
 95 Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO et al. 
Interindividual variability in acetaminophen glucuronidation by human liver 
microsomes: identification of relevant acetaminophen UDP-
glucuronosyltransferase isoforms. J Pharmacol Exp Ther 2001;299(3):998-1006. 
 96 Tougou K, Gotou H, Ohno Y, Nakamura A. Stereoselective glucuronidation and 
hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica 
2004;34(5):449-461. 
 97 Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA. An assessment of 
udp-glucuronosyltransferase induction using primary human hepatocytes. Drug 
Metab Dispos 2004;32(1):140-148. 
 98 Innocenti F, Iyer L, Ramirez J, Green MD, Ratain MJ. Epirubicin glucuronidation 
is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 
2001;29(5):686-692. 
 99 Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes 
morphine glucuronidation. Drug Metab Dispos 1997;25(1):1-4. 
 100 Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW et al. 3'-
azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-
glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000;28(5):497-
502. 
 101 Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and 
steroid glucuronidation by expressed human UDP-glucuronosyltransferases. 
Biochem Pharmacol 2003;65(9):1441-1449. 
 102 Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, Miners JO. 
Quantitative prediction of in vivo inhibitory interactions involving glucuronidated 
drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. 
Br J Clin Pharmacol 2006;61(4):427-439. 
 103 Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS et al. Effect of the 
UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug 
interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther 
2005;77(6):486-494. 
 104 Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, von Moltke 
LL et al. Stereoselective conjugation of oxazepam by human UDP-
glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, 
while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab 
Dispos 2002;30(11):1257-1265. 
 105 Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA. Impact 
of genetic polymorphisms of the beta2-adrenergic receptor on albuterol 
bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999;65(5):519-525. 
 106 EMA. Scientific Discussion. Herceptin (trastuzumab).  2005.  
 107 Rosenhagen MC, Uhr M. The clinical impact of ABCB1 polymorphisms on the 
treatment of psychiatric diseases. Curr Pharm Des 2011;17(26):2843-2851. 
 48 
 
 108 Reed K, Parissenti AM. The effect of ABCB1 genetic variants on chemotherapy 
response in HIV and cancer treatment. Pharmacogenomics 2011;12(10):1465-
1483. 
 109 The Human Cytochrome P450 (CYP) Allele Nomenclature Database. CYP 
alleles 2014; Available from: URL:http://www.cypalleles.ki.se/cyp2d6.htm 
 110 Dalen P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of 
nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. 
Clin Pharmacol Ther 1998;63(4):444-452. 
 111 Suarez-Kurtz G. Pharmacogenomics in admixed populations. Trends Pharmacol 
Sci 2005;26(4):196-201. 
 112 Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on 
warfarin dose requirements--a systematic review and meta-analysis. Eur J Clin 
Pharmacol 2009;65(4):365-375. 
 113 Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A. Several-fold increase in 
risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 
2005;78(5):540-550. 
 114 Fretzayas A, Moustaki M, Liapi O, Karpathios T. Gilbert syndrome. Eur J Pediatr 
2012;171(1):11-15. 
 115 Strassburg CP. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 
2008;9(6):703-715. 
 116 Duhme DW, Greenblatt DJ, Koch-Weser J. Reduction of digoxin toxicity 
associated with measurement of serum levels. A report from the Boston 
Collaborative Drug Surveillance Program. Ann Intern Med 1974;80(4):516-519. 
 117 Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin 
toxicity. Br J Anaesth 2005;95(4):434-441. 
 118 Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter 
Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for 
serotonin toxicity. QJM 2003;96(9):635-642. 
 119 Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to 
interaction between selective serotonin uptake inhibitors and non-steroidal anti-
inflammatory drugs. Aliment Pharmacol Ther 2008;27(1):31-40. 
 120 Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence 
of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the 
bioavailability of various antibiotics, including amoxicillin, cephalexin, 
doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 
1989;33(11):1901-1907. 
 121 Klein CE, Chiu YL, Cai Y, Beck K, King KR, Causemaker SJ et al. Effects of 
acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-
boosted atazanavir. J Clin Pharmacol 2008;48(5):553-562. 
 49 
 
 122 Tomilo DL, Smith PF, Ogundele AB, Difrancesco R, Berenson CS, Eberhardt E 
et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid 
suppression in healthy volunteers. Pharmacotherapy 2006;26(3):341-346. 
 123 Fraser DG, Ludden TM, Evens RP, Sutherland EW, III. Displacement of 
phenytoin from plasma binding sites by salicylate. Clin Pharmacol Ther 
1980;27(2):165-169. 
 124 Leonard RF, Knott PJ, Rankin GO, Robinson DS, Melnick DE. Phenytoin-
salicylate interaction. Clin Pharmacol Ther 1981;29(1):56-60. 
 125 Perucca E, Hebdige S, Frigo GM, Gatti G, Lecchini S, Crema A. Interaction 
between phenytoin and valproic acid: plasma protein binding and metabolic 
effects. Clin Pharmacol Ther 1980;28(6):779-789. 
 126 Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Pedersen KK. The 
long-term effect of verapamil on plasma digoxin concentration and renal digoxin 
clearance in healthy subjects. Eur J Clin Pharmacol 1982;22(2):123-127. 
 127 Cornwell MM, Pastan I, Gottesman MM. Certain calcium channel blockers bind 
specifically to multidrug-resistant human KB carcinoma membrane vesicles and 
inhibit drug binding to P-glycoprotein. J Biol Chem 1987;262(5):2166-2170. 
 128 Åsberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. Bilateral 
pharmacokinetic interaction between cyclosporine A and atorvastatin in renal 
transplant recipients. Am J Transplant 2001;1(4):382-386. 
 129 Shitara Y, Takeuchi K, Nagamatsu Y, Wada S, Sugiyama Y, Horie T. Long-
lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and 
OATP1B3-mediated uptake. Drug Metab Pharmacokinet 2012;27(4):368-378. 
 130 Teicher E, Vincent I, Bonhomme-Faivre L, Abbara C, Barrail A, Boissonnas A et 
al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics 
in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS 
HC-08 study. Clin Pharmacokinet 2007;46(11):941-952. 
 131 Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. The 
nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. 
Drug Metab Dispos 1996;24(10):1121-1123. 
 132 Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DA. The mechanism 
of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 
1987;42(4):388-394. 
 133 Yuen AW, Land G, Weatherley BC, Peck AW. Sodium valproate acutely inhibits 
lamotrigine metabolism. Br J Clin Pharmacol 1992;33(5):511-513. 
 134 Böttiger Y, Svensson JO, Ståhle L. Lamotrigine drug interactions in a TDM 
material. Ther Drug Monit 1999;21(2):171-174. 
 135 Annapandian VM, John GT, Mathew BS, Fleming DH. Pharmacokinetic 
interaction between sodium valproate and mycophenolate in renal allograft 
recipients. Transplantation 2009;88(9):1143-1145. 
 50 
 
 136 Reimann IW, Frolich JC. Effects of diclofenac on lithium kinetics. Clin 
Pharmacol Ther 1981;30(3):348-352. 
 137 Neuvonen PJ, Kivisto KT, Lehto P. Interference of dairy products with the 
absorption of ciprofloxacin. Clin Pharmacol Ther 1991;50(5 Pt 1):498-502. 
 138 Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA et al. 
Grapefruit juice increases felodipine oral availability in humans by decreasing 
intestinal CYP3A protein expression. J Clin Invest 1997;99(10):2545-2553. 
 139 Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with 
felodipine and nifedipine. Lancet 1991;337(8736):268-269. 
 140 Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics 
of atenolol. Eur J Clin Pharmacol 2005;61(5-6):337-340. 
 141 Andersson M, Lindh J.Granatäppeljuice kan interagera med warfarin. 
Lakartidningen 2012;109(9-10):483. 
 142 Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort 
(Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin 
Pharmacol 2002;54(4):349-356. 
 143 Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and 
herb-drug interactions: experience with Ginkgo biloba and omeprazole. 
Pharmacogenetics 2004;14(12):841-850. 
 144 Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S et al. Brief 
communication: American ginseng reduces warfarin's effect in healthy patients: a 
randomized, controlled Trial. Ann Intern Med 2004;141(1):23-27. 
 145 Seppälä NH, Leinonen EV, Lehtonen ML, Kivisto KT. Clozapine serum 
concentrations are lower in smoking than in non-smoking schizophrenic patients. 
Pharmacol Toxicol 1999;85(5):244-246. 
 146 Söderberg Löfdal KC, Andersson ML, Gustafsson LL. Cytochrome P450-
mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their 
clinical implications. Drugs 2013;73(6):533-543. 
 147 Funck-Brentano C, Turgeon J, Woosley RL, Roden DM. Effect of low dose 
quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of 
genetic polymorphism. J Pharmacol Exp Ther 1989;249(1):134-142. 
 148 Hovstadius B, Hovstadius K, Åstrand B, Petersson G. Increasing polypharmacy - 
an individual-based study of the Swedish population 2005-2008. BMC Clin 
Pharmacol 2010;10:16. 
 149 Haider SI, Johnell K, Thorslund M, Fastbom J. Trends in polypharmacy and 
potential drug-drug interactions across educational groups in elderly patients in 
Sweden for the period 1. Int J Clin Pharmacol Ther 2007;45(12):643-653. 
 150 Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease 
interactions in the ED: analysis of a high-risk population. Am J Emerg Med 
1996;14(5):447-450. 
 51 
 
 151 Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence 
and risk of potential cytochrome P450-mediated drug-drug interactions in older 
hospitalized patients with polypharmacy. Ann Pharmacother 2013;47(3):324-332. 
 152 Becker ML, Visser LE, van GT, Hofman A, Stricker BH. Increasing exposure to 
drug-drug interactions between 1992 and 2005 in people aged > or = 55 years. 
Drugs Aging 2008;25(2):145-152. 
 153 Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug 
reactions caused by drug-drug interactions. Expert Opin Drug Saf 2012;11(1):83-
94. 
 154 Personal communication, Johan Holm.  2014 Mar. 14.  
 155 SCB. Swedish Population Register, cited 2014 Mar. 20 
 156 Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. 
Hospitalisations and emergency department visits due to drug-drug interactions: a 
literature review. Pharmacoepidemiol Drug Saf 2007;16(6):641-651. 
 157 Böttiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesjö ML et al. 
SFINX-a drug-drug interaction database designed for clinical decision support 
systems. Eur J Clin Pharmacol 2009;65(6):627-633. 
 158 Baxter K, Preston CL. Stockley's Interactions Alert. URL: 
http://www.medicinescomplete.com 
 159 Yu DT, Seger DL, Lasser KE, Karson AS, Fiskio JM, Seger AC et al. Impact of 
implementing alerts about medication black-box warnings in electronic health 
records. Pharmacoepidemiol Drug Saf 2011;20(2):192-202. 
 160 Wong K, Yu SK, Holbrook A. A systematic review of medication safety 
outcomes related to drug interaction software. J Popul Ther Clin Pharmacol 
2010;17(2):e243-e255. 
 161 Weingart SN, Simchowitz B, Shiman L, Brouillard D, Cyrulik A, Davis RB et al. 
Clinicians' assessments of electronic medication safety alerts in ambulatory care. 
Arch Intern Med 2009;169(17):1627-1632. 
 162 van der Sijs, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van GT. 
Clinically relevant QTc prolongation due to overridden drug-drug interaction 
alerts: a retrospective cohort study. Br J Clin Pharmacol 2009;67(3):347-354. 
 163 Paterno MD, Maviglia SM, Gorman PN, Seger DL, Yoshida E, Seger AC et al. 
Tiering drug-drug interaction alerts by severity increases compliance rates. J Am 
Med Inform Assoc 2009;16(1):40-46. 
 164 Langemeijer M. Design specifications for drug-drug interaction alerts in 
computerized physician order entry systems: a preference study. [ University of 
Amsterdam; 2010. 
 165 Sweidan M, Reeve JF, Brien JA, Jayasuriya P, Martin JH, Vernon GM. Quality 
of drug interaction alerts in prescribing and dispensing software. Med J Aust 
2009;190(5):251-254. 
 52 
 
 166 Yu KH, Sweidan M, Williamson M, Fraser A. Drug interaction alerts in software-
-what do general practitioners and pharmacists want? Med J Aust 2011;195(11-
12):676-680. 
 167 Ko Y, Abarca J, Malone DC, Dare DC, Geraets D, Houranieh A et al. 
Practitioners' views on computerized drug-drug interaction alerts in the VA 
system. J Am Med Inform Assoc 2007;14(1):56-64. 
 168 Poirier TI, Giudici R. Evaluation of drug interaction microcomputer software: an 
updated comparison. Hosp Pharm 1995;30(10):888-4. 
 169 Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S et al. The 
largest prospective warfarin-treated cohort supports genetic forecasting. Blood 
2009;113(4):784-792. 
 170 Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad OP, Bergman U et 
al. The new Swedish Prescribed Drug Register--opportunities for 
pharmacoepidemiological research and experience from the first six months. 
Pharmacoepidemiol Drug Saf 2007;16(7):726-735. 
 171 R Core Team. R: A language and environment for statistical computing. Vienna, 
Austria:  R Foundation for Statistical Computing; 2012. 
 172 Bailey DG, Carruthers SG. Interaction between oral verapamil and beta-blockers 
during submaximal exercise: relevance of ancillary properties. Clin Pharmacol 
Ther 1991;49(4):370-376. 
 173 Shah NR, Seger AC, Seger DL, Fiskio JM, Kuperman GJ, Blumenfeld B et al. 
Improving acceptance of computerized prescribing alerts in ambulatory care. J 
Am Med Inform Assoc 2006;13(1):5-11. 
 174 Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the 
pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. 
Clin Pharmacol Ther 1999;66(1):33-39. 
 175 Gruber D, Cummings GG, LeBlanc L, Smith DL. Factors influencing outcomes 
of clinical information systems implementation: a systematic review. Comput 
Inform Nurs 2009;27(3):151-163. 
 176 Hayward J, Thomson F, Milne H, Buckingham S, Sheikh A, Fernando B et al. 
'Too much, too late': mixed methods multi-channel video recording study of 
computerized decision support systems and GP prescribing. J Am Med Inform 
Assoc 2013;20(e1):e76-e84. 
 177 Lapane KL, Waring ME, Schneider KL, Dube C, Quilliam BJ. A mixed method 
study of the merits of e-prescribing drug alerts in primary care. J Gen Intern Med 
2008;23(4):442-446. 
 178 van der Sijs H. Drug safety alerting in computerized physician order entry, 
unraveling and counteracting alert fatigue [ Erasmus University Rotterdam; 2009. 
 53 
 
 179 Hallas J, Gaist D, Bjerrum L. The waiting time distribution as a graphical 
approach to epidemiologic measures of drug utilization. Epidemiology 
1997;8(6):666-670. 
 180 Åstrand E, Åstrand B, Antonov K, Petersson G. Potential drug interactions during 
a three-decade study period: a cross-sectional study of a prescription register. Eur 
J Clin Pharmacol 2007;63(9):851-859. 
 181 Bergkvist A, Midlov P, Höglund P, Larsson L, Bondesson A, Eriksson T. 
Improved quality in the hospital discharge summary reduces medication errors--
LIMM: Landskrona Integrated Medicines Management. Eur J Clin Pharmacol 
2009;65(10):1037-1046. 
 182 Mannheimer B, Eliasson E. Drug-drug interactions that reduce the formation of 
pharmacologically active metabolites: a poorly understood problem in clinical 
practice. J Intern Med 2010;268(6):540-548. 
 183 Seidling HM, Storch CH, Bertsche T, Senger C, Kaltschmidt J, Walter-Sack I et 
al. Successful strategy to improve the specificity of electronic statin-drug 
interaction alerts. Eur J Clin Pharmacol 2009;65(11):1149-1157. 
 184 Strandell J, Caster O, Bate A, Noren N, Edwards IR. Reporting patterns indicative 
of adverse drug interactions: a systematic evaluation in VigiBase. Drug Saf 
2011;34(3):253-266. 
 185 White RW, Tatonetti NP, Shah NH, Altman RB, Horvitz E. Web-scale 
pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc 
2013;20(3):404-408. 
 186 Andersson ML, Lindh JD, Mannheimer B. The impact of interacting drugs on 
dispensed doses of warfarin in the Swedish population: A novel use of population 
based drug registers. J Clin Pharmacol 2013;53(12):1322-1327. 
 187 Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence 
from a routine therapeutic drug monitoring service. J Clin Psychiatry 
2007;68(10):1540-1545. 
 188 Aichhorn W, Marksteiner J, Walch T, Zernig G, Saria A, Kemmler G. Influence 
of age, gender, body weight and valproate comedication on quetiapine plasma 
concentrations. Int Clin Psychopharmacol 2006;21(2):81-85. 
 189 Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic 
consequences of the co-administration of lamotrigine and a combined oral 
contraceptive in healthy female subjects. Br J Clin Pharmacol 2006;61(2):191-
199. 
 190 Eriksson AS, Hoppu K, Nergardh A, Boreus L. Pharmacokinetic interactions 
between lamotrigine and other antiepileptic drugs in children with intractable 
epilepsy. Epilepsia 1996;37(8):769-773. 
 191 Shimamoto J, Ieiri I, Urae A, Kimura M, Irie S, Kubota T et al. Lack of 
differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy 
 54 
 
volunteers with respect to the single CYP2C9*3 allele. Eur J Clin Pharmacol 
2000;56(1):65-68. 
 192 Kumar V, Brundage RC, Oetting WS, Leppik IE, Tracy TS. Differential genotype 
dependent inhibition of CYP2C9 in humans. Drug Metab Dispos 
2008;36(7):1242-1248. 
 193 Botton MR, Hutz MH, Suarez-Kurtz G. Influence of the CYP2C9*3 allele on the 
pharmacological interaction between warfarin and simvastatin. 
Pharmacogenomics 2012;13(14):1557-1559. 
 194 Kuperman GJ, Bates DW, Teich JM, Schneider JR, Cheiman D. A new 
knowledge structure for drug-drug interactions. Proc Annu Symp Comput Appl 
Med Care 1994;836-840. 
 195 Center för eHälsa i samverkan. En samlad läkemedelslista.  2013.  
 
